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1 Introduction 
1.1 Ovarian cancer 
Ovarian cancer is one of the most deadly malignancies in women with 226,000 new cases 
and 140,000 deaths worldwide per year (Jemal et al., 2011). Despite increasing knowledge in 
the etiology of ovarian cancer and improvements in surgery and chemotherapy there has been 
little change in mortality. Delayed diagnosis due to a lack of specific symptoms and a lack of 
routinely used screening methods leads to diagnosis of about 75% of patients at advanced 
stages (III and IV). Five year survival rates decrease dramatically for these patients from over 
90% for International Federation of Gynecology and Obstetrics (FIGO) stage I to less than 40% 
for FIGO stages III and IV (Holschneider and Berek, 2000). Thus, markers for early detection 
of ovarian cancer to improve overall survival (OS) are urgently needed. 
 
Risk factors for ovarian cancer are a positive family history of ovarian cancer, null parity, 
refractory infertility and prior history of pelvic inflammatory disease, polycystic ovary 
syndrome and endometriosis. The major known hereditary predispositions for ovarian cancer 
are BRCA1 and BRCA2 mutations as well as familiar nonpolyposis colorectal cancer 
syndrome (also known as lynch II syndrome) caused by mutations in DNA mismatch repair 
genes. Protective factors for ovarian cancer are multiparity, the use of oral contraceptives, tubal 
ligation and hysterectomy. Currently valid prognostic factors include the patients’ performance 
status, age, stage of disease (classified according to the FIGO classification), tumor grade 
representing the degree of differentiation and the debulking status after cytoreductive surgery 
(Holschneider and Berek, 2000). 
 
FIGO classification for ovarian carcinoma consists of four stages (Odicino et al., 2008): 
stage I: growth limited to the ovaries 
stage II: growth involving one or both ovaries with extension limited to the pelvis 
stage III: growth involving one or both ovaries with histologically confirmed peritoneal 
implants outside the pelvis and/or positive retroperitoneal or inguinal nodes; superficial 
liver metastases equals stage III.  
stage IV: growth involving one or both ovaries with distant metastases; if pleural effusion 
is present, there must be positive cytology to allot a case to stage IV; parenchymal liver 
metastasis equals stage IV. 
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The degree of differentiation is usually scored by a three-tier tumor grading scheme: 
1 – low grade: well-differentiated tumors with well-structured papillae and few necrotic 
areas; cells exhibit low mitotic activity. 
2 – intermediate grade 
3 – high grade: poorly-differentiated tumors often forming solid masses with necrosis, 
hemorrhage and slit-like spaces; cells exhibit nuclear atypical phenotypes such as 
pleomorphic nuclei, nuclear enlargement, prominent nucleoli and high mitotic activity. 
 
Ovarian carcinomas are a heterogeneous group of distinct histological subtypes. 90% of 
ovarian cancers are of epithelial origin. Non-epithelial ovarian cancers comprise  
sex-cord-stromal tumors, germ-cell tumors and indeterminate tumors. Borderline (i.e. low 
malignant potential) tumors account for 10% to 20% of epithelial ovarian cancer (EOC). In 
invasive EOC, on which this study was confined, the following histological subtypes are the 
most important ones: serous (about 75% to 80%), mucinous (about 10%) and endometrioid 
(about 10%). Clear cell, small cell, undifferentiated and mixed cell are less common EOC 
histological subtypes (Holschneider and Berek, 2000). Generally, the histological subtypes of 
ovarian cancer differ considerable in their origin, epidemiology and mutation status. The term 
ovarian cancer mainly defines the location of dissemination (Vaughan et al., 2011).  
 
Two main genetic molecular pathways in serous tumorigenesis are known. i) Type I 
EOC: the low grade pathway describes the development of low grade carcinomas from benign 
cystadenomas through the transition state of borderline tumors. This pathway is characterized 
by mutations of the oncogenes BRAF and KRAS and microsatellite instability. Rare events in 
low grade carcinoma are p53 mutations leading to high grade carcinoma. ii) Type II EOC: the 
high grade pathway represents a de novo development of high grade carcinoma. EOCs of this 
type frequently have mutations causing genetic instability (Lax, 2009). 
In a recently published study by The Cancer Genome Atlas Research Network including 
hundreds of high grade serous EOC samples, which account for about 70% of ovarian cancer 
deaths, p53 mutations have been reported in 96% of tumors, BRCA1/2 germline or somatic 
mutations in about 20% and lost BRCA1 expression via promoter hypermethylation in 11%. 
Furthermore, the authors have described somatic mutations including the genes RB1, NF1, 
CSMD3, CDK12, BRAF, PIK3CA, KRAS and NRAS with a lower prevalence of 2% to 6%. 
More than 100 significant DNA copy number aberrations including amplifications encoding for 
CCNE1, MAPK1, KRAS and MECOM have been found in at least 10% of tumor samples. 
Deletions encoding for known tumor suppressor genes such as PTEN, RB1 and NF1 have been 
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found in at least 2% of tumor samples. Reduced expression of more than 150 genes including 
AMT, CCL21, SPARCL1, RAB25 and BRCA1 due to increased promoter methylation in 
tumors have been reported. Pathway analyses have indicated defective homologous 
recombination in about half of the studied cases and altered FOXM1 signaling in nearly 90% 
(TCGA, 2011). 
 
The question of the origin of ovarian cancer is still difficult to answer, especially because 
most tumors are diagnosed at advanced stages. Recent findings suggest that many ovarian 
cancer types derive from non-ovarian tissues (Vaughan et al., 2011). Prophylactic removing of 
the ovaries in high-risk patients revealed premalignant phenotypes or early stage carcinoma in 
numerous patients. Diagnosed tumors in these patients were all of the high grade type and 
localized in the area of the fallopian tubes indicating them as probable source of high grade 
tumors (Holschneider and Berek, 2000; Lax, 2009; Vaughan et al., 2011). 
However, two different models about the origin of serous ovarian carcinoma coexist: i) In 
the transformation theory, adenomas and cystadenomas develop from ovarian surface epithelia 
and from inclusion cysts of ovarian surface epithelia which undergo transformations causing 
malignant cell behavior. This theory is favored by the fact that inclusion cysts and ovarian 
carcinoma are associated with frequent ovulations (see below factors leading to ovarian 
carcinogenesis). ii) The transport theory postulates that serous carcinoma, mostly of the high 
grade type, arise from epithelial cells from the fallopian tubes which further metastasize to the 
ovary (Lax, 2009). According to latest publications, mucinous ovarian cancer often derives 
from the gastrointestinal tract, while endometrioid and clear cell ovarian cancer arises from 
endometriosis (Vaughan et al., 2011). The different origins of the histological subtypes of 
ovarian cancer are depicted in Figure 1. 
 
Until recently, the most favored theories about factors leading to ovarian carcinogenesis 
proposed that incessant ovulation causing repetitive disruption and repair of the ovarian 
epithelium bears a higher risk of spontaneous mutations leading to ovarian cancer. 
Consistently, women using oral contraceptives have a reduced risk of ovarian cancer. 
Alternatively, excessive gonadotropin stimulation and/or pelvic contaminants and carcinogens 
were believed to increase the risk of ovarian cancer (Holschneider and Berek, 2000). However, 
in light of new data indicating the fallopian tubes as probable origin of high grade serous EOC 
these theories have to be re-evaluated. 
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Figure 1. The origins of the histological ovarian cancer subtypes. Mucinous ovarian cancers are believed to derive from 
the gastrointestinal tract. Endometrioid and clear cell cancers are likely to have their origins in endometriosis. High grade 
serous ovarian cancers derive either from the ovarian surface or from the fallopian tubes (Vaughan et al., 2011). 
 
Residual tumor after cytoreductive surgery is one of the most important prognostic 
factors in EOC patients. However, several cut-off values for optimal surgical cytoreduction are 
in use. Most clinicians use cut-off values of macroscopic visibility, 1 or 2 cm for the presence 
of residual tumor load. A survival benefit of patients with residual disease ≤1 cm compared to 
patients with residual disease >1 cm has been reported. However, there is growing evidence 
that patients with no macroscopically visible residual tumor have better survival compared to 
women with visible residual disease ≤1 cm (Chang and Bristow, 2012). A study comprising 
only FIGO stage IV EOC patients has even described similar survival for patients with residual 
tumor of 0.1 to 1 cm and for patients with residual tumor >1 cm, while macroscopically 
complete resection has been associated with improved survival compared to both categories of 
residual tumor load (Wimberger et al., 2010). Together, these results support the current 
surgical approach aiming not only to reduce the tumor load, but to remove all macroscopically 
visible lesions. 
However, this cytoreductive surgery approach for EOC patients is complicated and 
involves risks. Not all patients might benefit to the same extent from this extensive surgery. 
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Thus, markers predicting patients’ survival benefit from the debulking surgery could help to 
decide to which extent aggressive cytoreductive surgery should be conducted in patients in 
whom optimal debulking is difficult and risky to achieve. 
 
1.2 Blood markers for EOC 
The poor prognosis of ovarian cancer and the lack of specific symptoms in early stages 
have caused great effort to establish screening programs to detect patients at early stages. 
Screening attempts include pelvic examinations, tumor marker measurements and 
ultrasonography. However, results are not satisfying and still, no additional screening marker 
for ovarian cancer is currently sensitive and specific enough for routine applications. The most 
widely used serum biomarker for ovarian cancer is cancer antigen 125 (CA125) with increased 
levels in more than 80% of ovarian cancer patients. However, the sensitivity for early stages is 
below 60%. Furthermore, the specificity of CA125 is limited since several benign 
gynecological (e.g. endometriosis) and medical conditions as well as other malignancies such 
as endometrial cancer and pancreatic cancer are characterized by increased CA125 levels. 
Additionally, higher CA125 levels are found in pre-menopausal women compared to women in 
post-menopause. Due to the impaired sensitivity and specificity of CA125 as an ovarian cancer 
biomarker many other serum markers have been evaluated in combination with CA125 such as 
leptin, prolactin, osteopontin, insulin-like growth factor II (IGF-II), macrophage migration 
inhibitory factor (MIF), human epididymis protein 4 (HE4), soluble mesothelin-related peptide 
(SMRP), CA72-4, human epidermal growth factor receptor 2 (HER-2/neu), inhibin and activin. 
But even the combination of several serum biomarkers do not reach required sensitivities and 
specificities (Moore et al., 2010). 
In the search for blood biomarkers for the diagnosis of cancer, besides serum proteins, 
also gene expression analyses of blood cells have been performed. As cancer interacts with the 
immune system, infiltrating leukocytes can be found in the tumor microenvironment and also 
the peripheral immune system reacts to the cancer. Therefore, the evaluation of peripheral 
immune cell gene expressions can serve as an indicator for a malignancy. However, most data 
about the systemic immune response to cancer have been published for mouse models, breast 
cancer and non-gynecological cancers, while the interaction of ovarian cancer with the systemic 
immune system remains to be further elucidated. For breast cancer, gene expression profiling of 
peripheral blood cells has been described for early detection (Aaroe et al., 2010; Sharma et al., 
2005).  
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Furthermore, blood biomarkers are of increasing scientific interest regarding their 
applicability as prognostic indicators for patients with a diagnosed malignant disease and to 
deduce therapeutic implications. There is evidence that a systemic inflammatory state is 
associated with a poor outcome in patients with malignant diseases including ovarian cancer 
(Hefler et al., 2008). Moreover, a link between the peripheral immune system and prognosis in 
human stroke (Urra et al., 2009) and tumor development in mice (Augier et al., 2010) has been 
established. However, the role of the peripheral immune system in chemotherapy response and 
(fatal) side effects is poorly understood. 
 
Recently, our working group has developed two molecular immune response signatures 
in blood leukocytes in in the course of the EU-project OVCAD (OVCAD–Ovarian Cancer: 
Diagnosis of a silent killer, www.ovcad.eu; coordinator Prof. Zeillinger, data not published). 
One of the gene signatures has been developed with the aim to detect EOC at early stages. The 
other gene signature has been developed with the aim to describe a prognostic signature for OS 
and death within two years after diagnosis in EOC patients. The gene names, function and 
corresponding Assay-on-demand TaqMan® probes of the genes comprised in the diagnostic and 
the prognostic gene signatures as well as the used housekeeping genes are summarized in Table 
1, 2 and 3, respectively. 
 
1.2.1 Diagnostic 13 gene panel 
The 13 gene panel for early detection of EOC includes the genes CFP, NOXA1, NEAT1, 
BC037918, DIS3, ZNF419, CCR2, B4GALT1, PAPOLG, PRIC285, AP2A1, C1orf63 and 
OSM (Table 1). A linear combination of the single expression values with coefficients listed in 
Table 1 is a measure of the relative risk of EOC and reaches a specificity of 99% and a 
sensitivity of 88%. 
The panel was developed by means of a whole genome transcriptomics microarray 
approach comparing expressions of 29,000 genes in a “high density” blood leukocyte fraction 
(see 2.3) from 44 EOC patients and 19 controls comprising healthy blood donors and patients 
with cystadenoma, a subsequent significance analysis of the microarray data and reverse 
transcriptase quantitative PCR (RT-qPCR). Finally the 13 gene panel was validated with 239 
EOC patients and 104 controls (healthy blood donors and patients with cystadenoma and low 
malignant potential tumors). In addition, abundances of six previously described plasma 
proteins were determined for 224 EOC patients and 65 controls: leptin, prolactin, osteopontin, 
IGF-II, MIF and CA125 (Visintin et al., 2008). The combined analysis of blood cell gene 
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expression and plasma protein based biomarkers in one model increases sensitivity and 
specificity which could allow earlier diagnosis. 
 
Table 1. Gene names and functions of the 13 genes of the diagnostic signature, corresponding Assay-on-Demand 
TaqMan® probes, regulation in ovarian cancer patients and coefficients of the combined diagnostic model. 
Gene 
symbol 
TaqMan® 
probe 
Gene name Function Regulationa 
Co-
efficients 
CFP Hs00175252
_m1 
complement factor properdin 
Alternative pathway for 
complement activation 
Down 
FC: -0.25 
0.28 
NOXA1 Hs01017917
_m1 
NADPH oxidase activator 1 Activates NADPH oxidases 
Down 
FC: -0.49 
-0.38 
NEAT1 Hs01008264
_s1 
non-protein coding RNA 84 Non-coding RNA 
Up 
FC: 1.53 
0.26 
BC037918 Hs00860048
_g1 
(no ORF in transcript BC037918) Non-coding RNA 
Up 
FC: 1.07 
0.34 
DIS3 Hs00209014
_m1 
DIS3 mitotic control homolog  
(S. cerevisiae) 
RNase, part of the exosome 
complex 
No 
(FC: 0.01) 
0.63 
ZNF419 Hs00226724
_m1 
zinc finger protein 419 Zinc finger protein 
No 
(FC: -0.07) 
0.05 
CCR2 Hs00356601
_m1 
chemokine (C-C motif) receptor 2 Chemokine receptor 
Up 
FC: 0.34 
0.26 
B4GALT1 Hs00155245
_m1 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypept. 1 
Galactosyltransferase 
No 
(FC: -0.21) 
0.15 
PAPOLG Hs00224661
_m1 
poly(A) polymerase gamma Poly(A) polymerase 
Down 
FC: -0.69 
-0.56 
PRIC285 Hs00375688
_m1 
peroxisomal proliferator-activated 
receptor A interacting complex 285 
Nuclear transcriptional 
coactivator for several nuclear 
receptors 
Down 
FC: -1.12 
-1.34 
AP2A1 Hs00367123
_m1 
adaptor-related protein complex 2, 
alpha 1 subunit 
Clathrin coat assembly 
Down 
FCb: -0.52 
-0.18 
C1orf63 Hs00220428
_m1 
chromosome 1 ORF 63 Unknown 
Down 
FC: -1.36 
0.64 
OSM Hs00171165
_m1 
oncostatin M IL-6 family cytokine 
Down 
FC: -1.14 
-1.05 
aSignificant down- or up-regulation in blood cells of EOC patients compared to healthy blood donors (T-test, corrected for multiple 
testing). 
bFC are actually log2-FC values. 
 
 
1.2.2 Prognostic seven gene panel  
The second gene signature has been described to predict OS and death within two years 
after diagnosis (with or without recurrence) in advanced stage EOC patients independently of 
other clinical parameters. It comprises the seven genes SRC, GUCY1B3, TUBB1, GUCY1A3, 
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TUBA8, EGF and TRIM14 (Table 2). For patients who died within two years after EOC 
diagnosis, one can assume that rather lethal side effects of the chemotherapy than the cancer 
per se caused the death. As described for the 13 genes, the seven gene panel derived from 
microarray data from 48 EOC patients’ “high density” blood leukocyte fractions (see 2.3) and 
was validated with RT-qPCR including 218 EOC patient samples. The seven genes were highly 
correlated with each other and most of them are involved in the gap junction pathway. Principal 
Component Analysis (PCA) was performed to reduce the complexity of the gene expression 
data. This analysis revealed that Principal Component 1 (PC1) (standing for 82% of data 
variance) and PC2 (standing for 9% of data variance) were indicators for OS and death within 
two years, respectively. 
According to published microarray data, among six key immune cell types (T cells, 
natural killer (NK) cells, B cells, monocytes and macrophages, dendritic cells (DCs) and 
neutrophils) SRC is mainly expressed in monocytes (Abbas et al., 2005). This finding and the 
high correlation of the seven genes with each other suggest that the genes of this panel are 
basically expressed by monocytes and its derivatives. 
 
Table 2. Gene names and functions of the seven genes of the prognostic signature, corresponding Assay-on-Demand 
TaqMan® probes and involved pathways. 
Gene 
symbol 
TaqMan® 
probe 
Gene name Function Pathway 
SRC 
Hs00178494_
m1 
Proto-oncogene tyrosine-protein 
kinase Src (short for sarcoma) 
Cell communication, embryonic 
development 
Gap junction 
GUCY1B3 
Hs00168336_
m1 
Guanylate cyclase soluble subunit 
beta-1 
Main receptor for nitric oxide Gap junction 
TUBB1 
Hs00258236_
m1 
Tubulin beta-1 
Mitosis, morphogenesis, platelet 
formation 
Gap junction 
GUCY1A3 
Hs01015570_
m1 
Guanylate cyclase soluble subunit 
alpha-3  
Main receptor for nitric oxide Gap junction 
TUBA8 
Hs01026795_
m1 
Tubulin alpha-8 
Mitosis, cell movement, 
development of neural structures. 
Gap junction 
EGF 
Hs01099999_
m1 
Epidermal growth factor 
Cellular proliferation, 
differentiation, and survival 
Gap junction 
TRIM14 
Hs00207648_
m1 
Tripartite motif containing 14 Development and cell growth  
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Table 3. Gene names of the three housekeeping genes and corresponding Assay-on-Demand TaqMan® probes. 
Gene 
symbol 
TaqMan® 
probe 
Gene name 
RPL21 
Hs03003806
_g1 
Ribosomal protein L21 
RPL9 
Hs01552541
_g1 
Ribosomal protein L9 
SH3BGRL3 
Hs00606773
_g1 
SH3 domain-binding glutamic 
acid-rich-like protein 3 
 
1.2.3  Which are the major immune cells involved in these two gene panels? 
There are two major possibilities describing the origin of the two gene signatures 
comprising gene expressions in a “high density” blood leukocyte fraction which is isolated 
using a density gradient (see 2.3): On the one hand, the expression characteristics could be due 
to differences in the relative amounts of certain immune cell types with constant expression 
levels; on the other hand, differences could be a result of altered gene expressions in a certain 
leukocyte population with a constant ratio; or a mixture of the two described possibilities. In 
both cases the causative leukocytes could comprise only one or several types of immune cells. 
Routine applications of the blood cell gene signatures require a more simple method than 
the density gradient to isolate the blood cell fraction which is used for the evaluation of the 
gene signatures. Such methods could base on a filtering system or on an immune magnetic 
separation of different blood cell fractions. To establish such an alternative method, for both 
described gene panels blood cell fractions have to be identified which permit the discrimination 
of EOC patients and healthy controls with the diagnostic panel and of EOC patients with 
favorable prognosis and those with a worse clinical outcome with the prognostic panel, 
respectively. Respective cell fractions isolated from the blood could overlap with cells present 
in the “high density” fraction or distinct blood cell types than the majority of cells in this 
fraction could be found to be more suitable for the determination of the gene signatures. If the 
latter is the case, a remodeling of the discriminative model could be necessary to reach required 
specificity and sensitivity. 
 
1.3 Tumor proliferation  
The proliferative ability of tumor cells, determined mostly by biomarkers such as Ki67, 
has been reported to have a different impact on prognosis in various malignancies. The protein 
Ki67 is located in the cell nucleus and is expressed during all active phases of the cell cycle, but 
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absent in resting cells. Ki67 immunohistochemical staining is used to determine the fraction of 
proliferating cells. 
On the one hand, high proliferation has been correlated with occurrence of metastases 
and subsequent worse clinical outcome (Gimotty et al., 2005). On the other hand, it has also 
been associated with improved OS and relapse-free survival (Fluge et al., 2009; Lee et al., 
2010). In ovarian cancer Ki67 proliferation index has been associated with advanced stage, 
high grade and complete responsiveness to first-line chemotherapy (Aune et al., 2011; Liu et 
al., 2012; Sengupta et al., 2000). Moreover, Ki67 has been found to be an independent 
prognostic factor for poor OS (Liu et al., 2012) and disease progression (Sengupta et al., 2000). 
Nevertheless, data are inconsistent and there are lacking data about the interaction of local 
immune processes and ovarian cancer growth.  
 
1.4 Tumor immunology 
The immune system of vertebrates consists of the innate and the adaptive immunity and 
is the major weapon in the defense against pathogens and foreign substances. The innate 
immunity with its instant anti-microbial mechanisms, including the skin barrier, proteins of the 
complement system and phagocytes, provides the early line of defense, while the adaptive 
branch combats infections with more advanced and specific armaments including lymphocytes 
and antibodies. In addition, the important role of the immune system in tumor destruction has 
become evident in recent years. 
 
Studies in mice have shown that immunodeficient animals spontaneously develop tumors 
and that they are much more susceptible to chemically induced tumorigenesis than 
immunocompetent animals. Moreover, the host immune status has been reported to be crucial 
for the immunogenicity of tumors since tumors from immunodeficient mice were more 
immunogenic than tumors from immunocompetent mice (Schreiber et al., 2011; Vesely et al., 
2011). 
Observations like this led to the development of the cancer immunoediting hypothesis 
consisting of three phases of tumorigenesis: elimination, equilibrium and escape. Elimination is 
the phase of cancer immunosurveillance when highly immunogenic transformed tumor cells are 
suppressed by the host’s innate and adaptive immune system. Tumor specific CD8+, CD4+ and 
γδ T cells, NK and NKT cells, DCs and pro-inflammatory, anti-tumoral M1 polarized 
macrophages accomplish the elimination of tumor cells (Schreiber et al., 2011). The 
  1 Introduction 
11 
 
polarization of macrophages and the associated functions are discussed in one of the following 
sections. 
In the second phase, equilibrium, anti-tumoral immune responses, on the one hand, and 
genetic instability and/or immunoselection of the tumor cells, on the other hand, lead to a 
balanced state of cancer persistence. This phase can last for years or decades. Immunoselection 
includes the killing of immunogenic cells by the immune system, whereas immunoresistant, 
poorly immunogenic and immunosuppressive tumor cells survive the immune attack and 
continue the malignant growth. A precondition for immunoselection is the genetic instability 
leading to mutations and a immunoresistant phenotype (Vesely et al., 2011). Experiments 
including the depletion and functional blocking of T and NK cells have shown that the 
immunological tumor control is most probably accomplished by the adaptive immunity. When 
T cells were affected, tumor progression was observed, while the blocking of NK cells had no 
effect on tumor growth. Besides the immunological control, tumor growth is restricted by 
apoptotic events and angiogenic limitations (Teng et al., 2008). 
The final escape phase is characterized by chronic inflammation, recruitment of 
immunosuppressive leukocytes and cancer progression. These immunosuppressive leukocytes 
inhibit inflammatory and cytotoxic effector functions of CD8+ T cells, NK cells and M1 
polarized macrophages. Moreover, down-regulations of proteins from the antigen processing 
and presentation machinery as well as up-regulations of apoptosis inhibitors have been 
described as characteristics for the tumor escape phase. Another mechanism of the tumor to 
evade immunosurveillance is the expression of molecules inducing the killing of T cells such as 
programmed death-1 ligand (PD-L1, also known as B1-H1) and Fas ligand (Schreiber et al., 
2011; Vesely et al., 2011). 
The multistage process of tumorigenesis includes the development of a tumor 
microenvironment providing a special ambience which favors the recruitment of 
immunosuppressive leukocytes and the inhibition of immune effector functions. Angiogenesis 
and the formation of lymphoid tissue-like structures which recruit and maintain 
immunosuppressing leukocytes are crucial steps in this process (Zindl and Chaplin, 2010). 
Such immune cells with suppressive functions are myeloid derived suppressor cells (MDSCs), 
regulatory T cells (Tregs), M2 polarized macrophages, T helper type 17 (Th17) cells, 
plasmacytoid DCs and immature tolerogenic DCs (Apetoh et al., 2011; Vesely et al., 2011; 
Zindl and Chaplin, 2010; Zou and Restifo, 2010). Chemokine and cytokine modulations cause 
the attraction of immune cells to the tumor site and can alter their polarization and inhibit their 
function. Among the most important molecules involved are interleukin-10 (IL-10), 
transforming growth factor-β (TGF-β), IL-1β, vascular endothelial growth factor (VEGF), 
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prostaglandin E2 (PGE2), granulocyte macrophage colony-stimulating factor (GM-CSF), 
CCL21 and CCL22 (Flavell et al., 2010; Vesely et al., 2011; Zindl and Chaplin, 2010). 
Moreover, inhibitory B7 molecules expressed by immune cells and by some tumors have 
immunosuppressive and protective functions (Zou and Chen, 2008).  
 
In humans, indications for tumor immunosurveillance are that immunosuppressed 
transplantation recipients and patients with AIDS have elevated risk for tumor development, 
whereby virus-associated malignancies predominate. More evidence for the interaction between 
the host immune response and malignancy provides the correlation between tumor disease and 
paraneoplastic autoimmune disorders due to cross-reactivity between the anti-tumoral immune 
response and neurologic antigens. Furthermore, signs of human immunosurveillance are 
antibody responses in the blood serum of patients against numerous tumor associated antigens 
and the presence of tumor infiltrating lymphocytes (TILs). Lymphocyte infiltrations have been 
described in cases of spontaneous tumor regression and correlated with the control of tumor 
outgrowth and improved patients’ survival (Vesely et al., 2011). 
 
Immune responses against malignancies as well as immune reactions during a microbial 
infection have to be balanced between immune-activating and immunosuppressing events. This 
balance is necessary to accomplish the elimination of transformed tumor cells and pathogens, 
respectively, while limiting host tissue destruction. However, many human tumors have been 
reported to alter the balance in favor of immune regulatory cells by remodeling the stromal 
tumor microenvironment and by secreting proteins promoting immunosuppressive cells and 
inhibiting effector T cell responses (Zindl and Chaplin, 2010). In the following sections the 
most frequently mentioned anti- and pro-tumoral leukocytes and their effector functions are 
discussed.  
 
1.4.1 Cytotoxic T lymphocytes 
Cytotoxic T lymphocytes belong to the adaptive immune system and are among the 
major weapons of cellular immunity against infected cells. Furthermore, they play a crucial role 
in tumor immunosurveillance. Cytotoxic T cells are characterized by a CD3+ (T cells)/CD8+ 
(cytotoxic T cells)/CD4- (T helper cells, regulatory T cells) phenotype. They recognize 
processed antigenic peptides presented in the class I major histocompatibility complexes 
(MHC-I) – in humans known as human leukocyte antigen (HLA) – of infected cells, allografic 
cells and tumor cells. The killing of the antigen presenting target cell is accomplished by the 
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release of the cytotoxic molecules perforin and granzymes A and B which enter the target 
cytosol and activate caspases that subsequently induce apoptosis. Moreover, killing by 
cytotoxic T cells can be induced by Fas/Fas ligand mediated apoptosis (Abbas et al., 2007). 
TILs are frequently found in tumor tissues indicating an ongoing host immune response. 
The prognostic value of host lymphocytes has been assessed in a variety of cancer entities 
(Galon et al., 2006; Gao et al., 2007; Zhang et al., 2003). Most studies have shown survival 
advantage associated with the presence of tumor infiltrating T cells (CD3+) and cytotoxic T 
cells (CD8+) (Gooden et al., 2011), while few studies revealed a non-significant prognostic 
value of CD3+ and/or CD8+ T lymphocytes (Gao et al., 2007; Nosho et al., 2010; Sorbye et al., 
2011).  
Despite the established anti-tumoral effect of T lymphocytes, these cells mostly fail to 
eliminate tumor mass. Tumors can even induce T cell tolerance. When naïve T cells recognize 
tumor associated antigens in the MHC complex on a tumor cell without a secondary 
costimulatory signal which is usually only provided by mature antigen presenting cells (e.g. 
DCs), they become anergic. Another mechanism to defang T cells is to induce their apoptosis 
by repetitive antigenic stimulation. Moreover, cytotoxic T cells are only one component of 
tumor infiltrating immune cells and are exposed to other immune cells exhibiting suppressive 
functions such as MDSCs, Tregs and M2 polarized macrophages (Yigit et al., 2010). 
 
1.4.2 Regulatory T cells (Tregs) 
The main phenotype of Tregs is CD4+/CD25+/FoxP3+. Tregs are capable of suppressing 
a wide range of immune cells such as T and B lymphocytes, NK, NKT and professional antigen 
presenting cells. Under non-pathogenic conditions they prevent autoimmunity by suppressing 
the activation of self-reactive T cells (Abbas et al., 2007). In various human cancer entities they 
have been described as a negative predictor of survival (Bates et al., 2006; Gao et al., 2007). 
Tregs occur naturally and can be induced. Both subtypes suppress effector T cell functions; the 
former ones in a cell-dependent manner (e.g. via the expression of immunoinhibitory cell 
surface molecules such as cytotoxic T lymphocyte antigen 4 (CTLA-4) and PD-L1) as well as a 
cytokine-dependent manner (mainly IL-10 and TGF-β); the latter ones suppress other cells via 
cytokines. They are recruited to the tumor site via CCL22 secreted by tumor cells and tumor 
associated leukocytes such as macrophages and DCs (Yigit et al., 2010). 
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1.4.3 Myeloid derived suppressor cells (MDSCs) 
MDSCs are a heterogeneous group of immature cells of the myeloid lineage with 
negative regulatory functions of immune responses in human cancer and other diseases. They 
comprise precursors of macrophages, DCs and granulocytes. They affect the adaptive immune 
system by suppressing different types of T cells as well as innate immune responses by 
modulating the cytokine profile of macrophages. One of their suppressive effects is the 
depletion of arginine which is essential for T cells. Its shortage inhibits T cell proliferation. 
Arginine is a substrate for the enzymes inducible nitric oxide synthase (iNOS) and arginase, 
both expressed in high levels by MDSCs. Moreover, nitric oxide (NO), a product of iNOS 
activity, affects T cell functions by inhibiting janus kinase 3 (JAK3) and signal transducer and 
activator of transcription 5 (STAT5) signaling, inhibiting MHC-II expression and inducing 
apoptosis. Other important mediators of the immunosuppressive mechanisms of MDSCs are 
reactive oxygen species (ROS) and peroxynitrite. Peroxynitrite causes nitration of the T cell 
receptor which leads to CD8 unresponsiveness to antigen-specific stimulation, while T cells 
remain responsive to non-specific stimulation. Furthermore, MDSCs have been reported to 
induce Tregs. In addition, MDSCs are involved in non-immunological, pro-tumoral 
mechanisms such as tumor angiogenesis, invasion and metastasis (Gabrilovich and Nagaraj, 
2009). In murine studies MDSCs have been described in ovarian cancer tissues (Yigit et al., 
2010). 
 
1.4.4 Macrophages 
Macrophages are cells of the innate immune system. They arise from circulating 
monocytes, which differentiate into tissue macrophages or closely related DCs. Tissue 
macrophages are a heterogeneous cell population and differentiate into distinct polarization 
stages depending on the environmental stimuli. Among their numerous functions are 
contribution to host defense, inflammation, tissue remodeling and immunosuppression. They 
maintain tissue homeostasis by removing apoptotic cells and repairing tissue after inflammation 
(Gordon and Martinez, 2010; Gordon and Taylor, 2005; Sica et al., 2002). 
Corresponding to the Th1 and Th2 cell polarization of T cells, two distinct activation 
states for macrophages have been described: i) the M1 or classically activated macrophages 
polarized by lipopolysaccharide (LPS) and interferon-γ (IFN-γ) and ii) the M2 or alternatively 
activated macrophages polarized by IL-4 and IL-13. 
M1 macrophages play an important role in the defense against viral and microbial 
infection, antigen presentation and tissue damage. They can release reactive nitrogen, ROS and 
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pro-inflammatory cytokines such as IL-12, IL-23 and tumor necrosis factor (TNF). Moreover, 
they recruit and stimulate other immune cells (e.g. Th1, NK cells). In contrast, M2 
macrophages participate in allergy, parasitic infections, dampening of inflammation, tissue 
remodeling and angiogenesis and accomplish immunoregulatory functions (Biswas and 
Mantovani, 2010; Gordon and Martinez, 2010). M2 macrophages are characterized by an  
IL-12low/IL-10high/IL-1 decoyRhigh/IL-1rahigh phenotype and high expression of scavenger and 
mannose receptors. Furthermore, M2 macrophages differ from M1 macrophages in their 
chemokine expression (e.g. CCL17, CCL22) (Mantovani et al., 2009). 
Macrophages can switch between the two functional stages. Intermediate or overlapping 
phenotypes have been observed during several diseases such as sepsis, cancer and obesity.  
M2-like forms of macrophage develop in response to e.g. glucocorticoids, TGF-β and IL-10. 
IL-10 stimulates the T cell inhibitory receptor PD-L1 on macrophages which mediates 
inhibition of T cell immunity (Biswas and Mantovani, 2010; Mantovani et al., 2009). 
 
Tumor associated macrophages (TAMs) are a prominent component of the leukocyte 
infiltrate in solid tumors (Gordon and Martinez, 2010; Sica et al., 2002). They mainly derive 
from circulating monocytes and are attracted by chemokines such as CCL2 produced in the 
tumor microenvironment (Mantovani et al., 2002). Moreover, tumor cells promote M2-like 
polarization and can inhibit classical macrophage effector functions such as cytotoxicity via 
cytokines including TNF, IL-10 and TGF-β. On the one hand, M1-like TAMs can prevent the 
establishment and spread of tumor cells and are characterized by tumoricidal activity. TAMs 
can also produce anti-angiogenic molecules such as plasminogen activator inhibitor type 2 
(PAI-2) and thrombospondin 1 (TSP1). On the other hand, M2-like TAMs can support tumor 
progression and dissemination by suppression of cells of the adaptive immunity such as Th1 
cells and cytotoxic T lymphocytes, remodeling of the extracellular matrix and expression of 
angiogenic factors such as VEGF and epidermal growth factor (EGF). Moreover, they 
contribute to metastasis and invasion through cathepsin B and S and recruit other hematopoietic 
cells through chemokines (Biswas and Mantovani, 2010; Gordon and Martinez, 2010; Sica et 
al., 2002). M2-like TAMs also promote cancer-related inflammation, an event which has 
recently been added to the hallmarks of cancer and which promotes tumorigenesis and tumor 
progression (Hanahan and Weinberg, 2011). These diverse functions reflect the phenotypic 
heterogeneity of TAMs with M1- and M2-like properties. 
TAMs have many properties of M2-like macrophages (Gordon and Martinez, 2010). 
However, this cannot be generalized for all tumor types and substantially different macrophage 
phenotype compositions can even be found in different areas within the same tumor. Moreover, 
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the M2-like phenotype of TAMs is reversible: Classical activation can be achieved by IFN-γ, 
activation of toll-like receptor 9 (TLR-9) and blocking of IL-10 (Biswas and Mantovani, 2010). 
In concordance with the described functions of M2-like TAMs, TAMs have been associated 
with a poor prognosis in various cancer entities (Biswas and Mantovani, 2010; Mantovani et 
al., 2009; Mantovani et al., 2002; Pollard, 2004). 
 
Given the limited number of published studies regarding human macrophages, a 
consensus of markers for M1 and M2 polarization has not been established so far (Gordon and 
Martinez, 2010). For M1 high expression of CD16, CD32, CD64, CD80, CD86, HLA-DR and 
iNOS has been reported, whereas M2 are characterized by up-regulation of mannose and 
scavenger receptors, CD163, CD23 and arginase (Escorcio-Correia and Hagemann, 2010; 
Mantovani et al., 2002). However, M1 and M2 polarization represents the extremes of a 
continuum of possible polarization states, while TAMs can present characteristics of both (e.g. 
simultaneous expression of iNOS and arginase) (Escorcio-Correia and Hagemann, 2010).  
 
1.4.5 The immunosuppressive microenvironment of ovarian cancer 
In contrast to many other cancer entities, ovarian cancer disseminates by metastasizing 
the peritoneal cavity whose special immunosuppressive environment protects the cancer from 
immune destruction. Distant metastases are rare and – if detectable – they do not significantly 
contribute to mortality in ovarian cancer patients. 
A variety of tumor infiltration leukocytes and their impact on the outcome have been 
studied in ovarian cancer patients. Intraepithelial CD8+ TILs in ovarian tumor tissues have 
been described to play a major role in anti-tumoral activity and survival (Leffers et al., 2009). 
In contrast, no significant correlation of stromal CD8+ cells and survival has been reported 
(Hamanishi et al., 2007; Milne et al., 2009; Sato et al., 2005). A currently published  
meta-analysis has also confirmed the prognostic significance of TILs (CD3+ and CD8+) in 
ovarian cancer patients (Hwang et al., 2012). Nevertheless, the tumor is rarely eradicated 
efficiently, but it manages to escape from immune elimination supported by 
immunosuppressive cells. In ovarian cancer Tregs have been shown to suppress anti-tumoral  
T cell immunity and have been associated with a worse clinical outcome (Curiel et al., 2004). 
TAMs in ovarian cancer have already been subject of several studies which have indicated an 
immunosuppressive M2-like polarization (Kawamura et al., 2009; Wang et al., 2010). 
Moreover, ovarian cancer TAMs expressing B7-H4 have been described to inhibit T cell 
immunity and to have a negative impact on patients’ outcome (Kryczek et al., 2007; Kryczek et 
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al., 2006). However, further information about the prognostic value of M1 and M2 polarized 
TAMs in ovarian cancer patients is needed. 
As a result of this immunosuppressive milieu in the peritoneal cavity ovarian cancer is 
able to grow and able to metastasize the abdomen. Thus, effective immune therapies should 
consist of a combination of immune activating strategies and the limitation of 
immunosuppressive mechanisms, for instance targeting Tregs, M2 polarized macrophages and 
MDSCs and/or the suppressive cytokines involved.  
 
1.5 Aim of this study 
The work in the course of my diploma thesis aimed at the question of the relationship 
between the peripheral immune system, the tumor proliferative activity and tumor immune cell 
infiltration in EOC patients and the clinical relevance of these factors. 
 
The peripheral immune system was represented by the two blood cell gene expression 
signatures recently developed in our group, one for early diagnosis of EOC and one for 
prognosis of OS and death within two years after diagnosis in EOC patients. A more simple 
methods than the described density gradient such as a filtering system or an immune magnetic 
separation system for whole blood would render the determination of the two described gene 
signatures more suitable for routine use. To facilitate the protocol applying such a method, the 
panels require further analysis to identify the most important blood cells involved. Therefore, 
the expression patterns of the genes comprised in the two panels were determined in different 
blood cell fractions (monocytes, monocyte derived immune cells, granulocytes, B and T 
lymphocytes, NK cells etc.) from 23 patients using RT-qPCR. The analysis of the diagnostic 
gene panel included the comparison of the expression values of each gene in each blood cell 
fraction between patients according to the disease in order to find cell fractions presenting 
significant differences between EOC patients and controls. The characterization of the 
prognostic gene signature was approached by comparing the gene expression values in the 
different blood cell fractions. The aim of this primary, rough analysis of the different blood cell 
fractions was to search a candidate cell fraction or a combination of cell fractions which permit 
the discrimination of i) EOC patients and controls with the diagnostic panel and of ii) EOC 
patients with a favorable outcome and those with reduced survival time with the prognostic 
panel. The next step would be to establish a possibly short and simple separation protocol to 
isolate the respective cell type(s) which can substitute the density gradient for the determination 
of the respective gene signature. Furthermore, confining or identifying the cell type(s) involved 
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could improve specificity and sensitivity of the diagnostic gene signature and strengthen the 
predictive value of the prognostic gene signature.  
 
Besides the peripheral immune system of EOC patients, the tumor microenvironment in 
ovarian cancer patients was another target of interest of this work. The tumor proliferative 
activity, a marker for intrinsic tumor aggressiveness and velocity of growth, was assessed. 
Moreover, tumor infiltrating leukocytes which indicate an ongoing host immune response 
against the cancer were analyzed. The obtain information about a broad range of leukocytes, 
infiltration levels of cytotoxic T cells as representatives of the adaptive immune system, of 
macrophages as representatives of the innate immune system and of leukocytes in general were 
determined in more than 200 EOC tumor samples using immunohistochemical staining 
techniques. Interactions between tumor proliferation and immune cells were assessed. Special 
focus of the diploma thesis was the association of the proliferation status and the different 
leukocyte infiltrations with clinical outcome parameters such as survival time and 
chemotherapy response. 
 
In addition, the systemic and local immune reactions were linked by assessing the 
interaction of the prognostic gene panel and TAMs in patients with the lowest and highest risk 
to die and risk of death within two years after EOC diagnosis (according to the prognostic 
blood cell gene expression panel). The number of macrophages in the tumor tissue and their 
polarization were determined using immunofluorescent staining techniques. Correlation 
analysis of the TAM data and the parameters from the prognostic gene signature should help to 
understand if the risk to die and the risk of death within two years after diagnosis of EOC 
patients measured by blood cell gene expression values are also reflected in the macrophage 
population (number and/or polarization) in the tumor tissue. 
 
The major goal of this diploma thesis was to assess different aspects of host immune 
responses to ovarian cancer patients with special attention on survival analyses and possible 
implications for clinical purpose such as markers for early diagnosis and prognosis as well as 
therapy and surgery of EOC patients.  
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2 Materials and methods 
2.1 Study population and patients’ materials 
Blood: Pre-operative blood from ten patients with suspicion of EOC and 13 female 
controls, comprising patients with benign gynecological diseases and healthy persons, were 
enrolled in the study. Patients have been recruited between March 2011 and January 2012 in 
the Department of Obstetrics and Gynecology, Medical University of Vienna, Austria. EOC 
could not be confirmed before histological examination. Therefore, some of the patients with 
suspicion of EOC were subsequently re-diagnosed and summarized in a separate patient cohort. 
 
Tumor tissue: Patients derived from the OVCAD cohort. Only EOC patients with FIGO 
stage II, III and IV were enrolled in the study. They have been recruited from 2005 to 2008 in 
the Department of Gynecology at Charité, Campus Virchow-Klinikum, Medical University 
Berlin, Germany; Department of Obstetrics and Gynecology and Gynecologic Oncology, 
University Hospital Leuven, Belgium; Department of Gynecology, University Medical Center 
Hamburg-Eppendorf, Germany; Department of Obstetrics and Gynecology, Medical University 
of Vienna, Austria; Department of Gynecology and Obstetrics, Innsbruck Medical University, 
Austria. A broad and well-described tumor bank and database consisting of clinical and 
histopathological data as well as follow-up data were established. 
Patients with other malignancies were excluded. All EOC patients were treated according 
to standardized protocols with cytoreductive surgery combined with a platinum/taxane based 
chemotherapy for six courses. Operable patients were treated with adjuvant chemotherapy after 
cytoreductive surgery, while initially inoperable patients were treated with neoadjuvant 
chemotherapy to reduce tumor load prior to surgery, followed by cytoreductive surgery and 
subsequent adjuvant chemotherapy. Residual tumor load was defined as negative if 
macroscopically absent. 
Despite the impaired sensitivity and specificity of pre-operative CA125 level as a 
diagnostic marker, it is a well-established measurement for progression of disease and 
treatment response. The disease progression was determined according to the RECIST criteria 
(Rustin, 2003). Briefly, nadir serum CA125 levels ≤35 U/mL in the course of first-line adjuvant 
chemotherapy were defined as negative. Following control examinations were performed every 
three months during the first two years and subsequently every six months until five years after 
first-line therapy for patients without clinical complaints. Patients with complaints were 
2 Materials and Methods 
20 
 
additionally examined. Disease progression was defined as CA125 values >70 U/mL 
documented on two occasions for patients with negative CA125 after first-line chemotherapy or 
as a doubling of the nadir CA125 documented on two occasions for patients with values  
>35 U/mL. The time point of disease progression was the first date of CA125 elevation. 
Besides serum CA125, radiological techniques were used to assess disease progression. Disease 
progression during first line platinum-based therapy or within four weeks after the last 
chemotherapy cycle was defined as refractory disease (Friedlander et al., 2011). OS was 
defined as the time interval between diagnosis of ovarian cancer and tumor-related death. 
Progression-free survival (PFS) was defined as the time between cytoreductive surgery and 
progression of disease. Patients with refractory disease were excluded from PFS analyses since 
the time point of progression of disease could not be reliably determined. Patients were 
censored at their last follow-up or after death from tumor-unrelated causes. 
Informed consent for the scientific use of biological material was obtained from all 
patients and healthy blood donors in accordance with the requirements of the ethics committee. 
Experienced gynecological oncologists and pathologists of the participating universities 
performed the clinical and histopathological evaluation. 
 
A total of 209 patients were included in the immunohistochemical study of tumor 
infiltrating leukocytes and tumor proliferation. Tissue microarrays (TMAs) comprising tumor 
tissues of these patients were used for the immunohistochemical staining. 
 
A number of 19 patients, mainly overlapping with the 209 patients from the 
immunohistochemical study, were included in the study analyzing TAMs with 
immunofluorescent staining. They were selected according to their expression values of genes 
from the prognostic signature that had been developed recently in our working group. As 
outlined in the introduction, PCA performed with gene expression data of this signature 
revealed PC1 and PC2 as indicators of OS and death within two years after EOC diagnosis, 
respectively. 19 patients with extreme high or low PC1 and PC2 values were selected. Whole 
tissue sections (WTSs) were used for the immunofluorescent staining. 
 
2.2 Cell separation from whole blood 
Cell separation from pre-operative whole blood was performed with the Pluriselect 
technology using provided protocols and reagents (pluriBead® Kit Cascade, Cell lysis protocol, 
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pluriSelect, Germany). Per patient approximately 12 mL EDTA-anticoagulated whole blood 
were used for the Pluriselect cell separation with 62 µm-bead-coupled antibodies against CD3 
(T cells), CD15 (granulocytes and monocytes) and CD44 (tissue cells, leukocytes and 
erythrocytes) and 32 µm-bead-coupled antibodies against CD14 (monocytes), CD19 (B cells) 
and CD25 (activation marker for several immune cells, predominantly of the lymphoid 
lineage). CD14+ and CD15+ cells were enriched without a second antibody, whereas the 
enrichment of CD3+ and CD19+ cells as well as of CD25+ and CD44+ cells was performed in 
the same reaction tube by adding 62 µm-bead-coupled antibodies for the capture of one cell 
type and 32 µm-bead-coupled antibodies for the capture of the other cell type. About 3 mL 
whole blood were used for the enrichment of the different cell fractions: CD14, CD15, 
CD3/CD19 and CD25/CD44. Before the enrichment of CD14+ cells soluble CD14 was 
removed from the plasma by washing the whole blood twice with the double volume of wash 
buffer (300 g, without break, 10 minutes). The sample material was transferred to mixing 
containers provided in the kit and 40 µL bead-labeled antibody suspension (concentration not 
designated) per mL whole blood were added. The samples were mixed for 45 minutes at room 
temperature on a horizontal roller mixer (pluriPlix®, pluriSelect, Germany). 
 
Microscopic examination of the blood samples that had been simultaneously incubated 
with antibodies against CD3/CD19 and CD25/CD44, respectively, was performed to rule out 
the binding of antibodies coupled to different sized beads to the same cells. 
 
The cell strainers corresponding to the size of the beads coupled to the antibodies were 
attached to the mixing containers. For the simultaneous enrichment of cells captured with  
62 µm-bead-coupled antibodies and cells captured with 32 µm-bead-coupled antibodies two 
cell strainers were attached onto each other, whereby the 57 µm-cell strainer for the  
62 µm-beads was the first in the cascade followed by the 27 µm-cell strainer for the  
32 µm-beads. The mixing containers with the strainers were inverted and attached to a 50 mL 
tube. The mixing container and the strainers were extensively washed with wash buffer to 
remove unbound cells and to forward the smaller beads onto the second strainer. For the 
simultaneous enrichment of two cell types the cell strainers were separated from each other, 
attached to 50 mL tubes and washed again. The principle of the multi-target cell separation is 
depicted in Figure 2. 
Finally, the strainers were attached to fresh 50 mL tubes with connector rings. Twice  
350 µL RLT lysis buffer (QIAGEN, Netherlands) were applied to each cell strainer, lysates 
were collected from the tubes and stored at -20°C. 
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2.3 Isolation of a “high density” blood leukocyte fraction from whole blood 
A “high density” (HD) blood leukocyte fraction (density greater than 1.077 g/mL) 
depleted from the majority of peripheral blood mononuclear cells (PBMCs) and possibly 
present circulating tumor cells (CTCs) was obtained by performing a density gradient using 5 
mL EDTA-anticoagulated whole blood, largely according to Brandt and Griwatz (Brandt and 
Griwatz, 1996). The granulocyte- and lymphocyte-rich HD fraction above the erythrocytes 
pellet and below the CTC/PBMC fraction was aspirated and washed twice with PBS (Figure 3). 
Washed cell pellets were lysed in 400 µL RLT lysis buffer (QIAGEN, Netherlands). 
 
 
 
 
Figure 2. The principle of simultaneous separation of two target cells with one sample 
(figure taken from http://pluriselect.com/multi-target-separation.html; 20.06.2012). 
Figure 3: Blood gradient used to isolate a “high density” (HD) blood 
leukocyte fraction (density greater than 1.077) depleted from circulating 
tumor cells (CTCs) and peripheral blood mononuclear cells (PBMCs). 
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2.4 RNA extraction 
Blood cell fractions: Total RNAs from lysates of fractions of enriched CD3+, CD14+, 
CD15+, CD19+, CD25+ and CD44+ cells and from the HD fraction lysates were isolated using 
the RNeasy Micro kit and the RNeasy Mini kit (QIAGEN, Netherlands), respectively, 
according to the manufacturer’s instructions. RNA concentrations were measured 
spectrophotometrically. 
 
Tumor tissues: About 30 mg fresh frozen tumor tissue of the 160 available tumor samples 
were homogenized by beadbeating at 2000 rpm for 90 seconds, using a Mikro-Dismembrator U 
(B. Braun, Biotech International) and lysed in 1 mL Nucleic Acid Purification Lysis Solution 
(Applied Biosystems, Life Technologies, USA). Total RNA from the lysates was isolated with 
the ABI PRISM 6100 Nucleic Acid PrepStation using provided protocols and reagents (Tissue 
RNA isolation, Applied Biosystems, Life Technologies, USA) and quantified 
spectrophotometrically. The quality of RNA was assessed with an Agilent 2100 Bioanalyzer. 
RNA with an RNA Integrity Number (RIN) >5 was used for the study. 
 
2.5 cDNA synthesis 
Blood cell fractions: The following protocol was used for cDNA synthesis with up to  
500 ng RNA in a total reaction volume of 25 µL: For samples with RNA amounts less than  
500 ng, the available RNA amount was used. RNA and the random nonamer primer were 
incubated for 5 minutes at 70°C and quick-chilled on ice. 
 
15.56 µL   RNA (≤500 ng) 
2.5 µL  Random-Nonamer (100 µM) 
18.01 µL   5 min 70°C, ∞ 4°C 
 
The following reagents were added to the RNA-nonamer-mixture and the reaction mix 
was incubated for 15 minutes at 25°C, for 50 minutes at 45°C and for 10 minutes at 55°C. 
 
18.01 µL  RNA-nonamer-mixture 
5 µL  5x M-MLV RT 5x Buffer    Promega, USA 
0.625 µL  dNTP Mix (20 mM)     GE Healthcare, Life Sciences, UK 
0.3125 µL  RNasin® Plus RNase inhibitor (40 U/µl)   Promega, USA 
1 µL  M-MLV RT, RNase H(-) Point Mutant (200 units/µL)  Promega, USA 
25 µL   15 min 25°C, 50 min 45°C, 10 min 55°C, ∞ 4°C 
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Tumor tissues: The cDNA synthesis was performed with the Omniscript Reverse 
Transcription Kit (QIAGEN, Netherlands) with 500 ng RNA according to manufacturer’s 
instructions. Random hexamer primers and RNasin® Plus RNase inhibitor (40 U/µl) (Promega, 
USA) were used. 
 
2.6 qPCR 
qPCR was performed according to the following scheme: 
 
 2 µL  cDNA sample* 
 0.4 µL  20x TaqMan Gene Expression Assay  Applied Biosystems, Life Technologies, USA 
 4 µL  2x TaqMan Gene Expression MasterMix  Applied Biosystems, Life Technologies, USA 
 1.6 µL  H2O 
8 µL  
 
* cDNA dilution: blood cell fractions: 1:8 ; tumor tissue: 1:2 
 
The reaction mixture was pre-incubated at 50°C for two minutes and at 95°C for ten 
minutes, followed by 50 cycles of two step incubation at 95°C for 15 seconds and at 60°C for 
one minute. Each PCR was performed in duplicates. 
 
Blood cell signatures: TaqMan gene expression assays for the 13 genes from the 
diagnostic panel, CFP, NOXA1, NEAT1, BC037918, DIS3, ZNF419, CCR2, B4GALT1, 
PAPOLG, PRIC285, AP2A1, C1orf63 and OSM, and the seven genes from the prognostic 
panel, SRC, GUCY1B3, TUBB1, GUCY1A3, TUBA8, EGF and TRIM14, were used with the 
cDNA samples from the patients’ seven blood cell fractions. The three stably expressed 
housekeeping genes RPL21, RPL9 and SH3BGRL3 were used as reference. In Table 1, 2 and 3 
the TaqMan gene expression assays are summarized. 
 
Tumor tissues: The qPCR was performed with the CD8A TaqMan Gene Expression 
Assay (Hs00233520_m1, Applied Biosystems, Life Technologies, USA) according to the 
manufacturer’s instructions. The housekeeping gene GAPDH (Hs99999905_m1, Applied 
Biosystems, Life Technologies, USA) was used as reference.  
A calibrator consisting of a mixture of cDNAs from HD blood leukocyte fractions and 
tumor cell lines was used.  
 
  2 Materials and methods 
25 
 
2.7 Evaluation of RT-qPCR data 
The mean value of the duplicate RT-qPCR expression values (Ct values) was calculated: 
for the analysis of the two blood cell signatures the 23 gene expression assays (13 genes of the 
diagnostic panel, seven genes of the prognostic panel and three housekeeping genes) in 161 
blood fraction samples (23 patients with each seven fractions) and in the calibrator sample; for 
the analysis of CD8 gene expression in the tumor tissues the CD8A and the GAPDH assays in 
160 tumor samples and in the calibrator sample. When the standard deviation was greater than 
1, only the smaller Ct value was used assuming that deviations occurred due to pipette errors 
resulting in lower cDNA volumes and consequently higher Ct values. The geometric mean of 
the mean Ct values of the three housekeeping genes (blood samples) and the mean Ct value of 
the reference gene GAPDH (tumor tissue samples) were calculated for each sample and 
normalized with the mean calibrator Ct value (calibrator normalized mean of the reference). 
The mean Ct values were normalized with the mean calibrator Ct value of the corresponding 
assay and with the calibrator normalized mean of the reference. Finally the normalized Ct 
values were multiplied by -1 to be interpretable as log2-expression values (relative expression 
values). 
 
2.8 Immunohistochemical and -fluorescent staining 
Primary tumors were fixed in formalin and embedded in paraffin using standardized 
procedures. Per patient a representative tumor block was selected. TMA were assembled using 
two 1 mm cores per patient. 
If not otherwise indicated described procedures were performed at room temperature. 
Four µm sections were put onto highly adhesive slides (Thermo Scientific SuperFrost Ultra 
Plus, Thermo Fisher Scientific, USA), deparaffinized and rehydrated. After antigen heat 
retrieval by microwaving the slides in EDTA (1mM, pH 8) for 15 minutes slides were cooled to 
room temperature. In the immunohistochemistry (IHC) protocol next endogenous peroxidase 
activity was quenched by incubation the samples with 3% H2O2 in methanol for ten minutes. In 
the immunofluorescence (IF) protocol the blocking step directly followed the antigen heat 
retrieval omitting the peroxidase quench. Blocking solution (Ultra V Block; TA-015HP, 
Thermo Fisher Scientific, USA) was applied to the samples for seven minutes before 
incubation with monoclonal antibodies overnight at 4°C. 
Lymphoid tissues samples (lymph node, tonsil, spleen) served as positive control for the 
leukocyte markers. Normal colon tissue served as positive control for the cell proliferation 
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marker Ki67. Mouse IgG1 (1:50; Negative Control Mouse IgG1, code X0931, Dako, Denmark) 
was used as mouse isotype control. As for rabbit antibodies no useful isotype control was 
available, primary antibody was omitted as negative control. 
 
IHC: After blocking antibodies against the cytotoxic T cell marker CD8 (1:1000, clone 
C8/144B, source mouse, isotype IgG1, Dako, Denmark), against the macrophage marker CD68 
(undiluted, clone KP1, source mouse, isotype IgG1, ThermoScientific, USA), against the 
panleukocyte marker CD45 (1:8000, clone E19-GDB, source rabbit, DB Biotech, Slovakia) and 
against the cell proliferation marker Ki67 (1:75, clone MIB-1, code M7240, source mouse, 
isotype IgG1, Dako, Denmark) were applied. For detection the UltraVision detection system 
(Thermo Fisher Scientific, USA) and the Dako LSAB System (Dako, Denmark) were used 
according to the manufacturers’ protocols. The UltraVision detection system was used for the 
detection of bound antibodies against CD8, CD68 and CD45. Bound antibody against Ki67 was 
detected using the Dako LSAB System (Dako, Denmark). Sections were incubated either with 
Primary Antibody Enhancer (TL-015-PB, Thermo Fisher Scientific, USA) for ten minutes and 
subsequently with horseradish peroxidase (HRP) Polymer (HRP Polymer; TL-015-PH, Thermo 
Fisher Scientific, USA) for 15 minutes or with Dako Biotinylated Link (K0675, Dako, 
Denmark) for 15 minutes followed by Dako Streptavidin-HRP (K0675, Dako, Denmark) for 15 
minutes. Slides were stained with diamino-benzidine (DAB) (DAB Chromogen 1:50 in DAB 
Substrate Buffer, K0673, Dako, Denmark) for two minutes. For counterstaining, the slides were 
dipped into hematoxylin for 25 seconds. Slides were mounted with Eukitt® (O. Kindler, 
Germany). 
 
IF: A double staining with primary monoclonal antibody against the macrophage marker 
CD68 (1:15, clone KP1, source mouse, isotype IgG1, ThermoScientific, USA) and primary 
antibody against the M2 polarization marker macrophage scavenger receptor 1 (MSR1) (1:200, 
HPA000272, source rabbit, Sigma, USA) was performed. The fluorescence labeled secondary 
antibodies goat anti-mouse (1:1000, AlexaFluor® 568 F(ab’) fragment of goat anti-mouse IgG 
(H+L), Invitrogen, Life Technologies, USA) and goat anti-rabbit (1:1000, AlexaFluor® 647 
F(ab’) fragment of goat anti-rabbit IgG (H+L), Invitrogen, Life Technologies, USA) were 
incubated for one hour. For nuclear counterstaining, slides were incubated with DAPI  
(0.5 µg/mL) for five minutes. Slides were mounted with Fluoromount-GTM (Southern Biotech, 
USA). 
In addition test staining for CD68 in combination with potential M1 macrophage markers 
(and the M2 marker MSR1) was performed. Monoclonal primary antibodies against CD80 
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(1:300, clone EP1155Y, source rabbit, Abcam, UK), against iNOS (1:200, clone K13-A, source 
rabbit, DB Biotech, Slovakia) and against HLA-DR (1:300, clone LN3, source mouse, isotype 
IgG2b, ThermoScientific, USA) were tested for their applicability for M1 macrophage detection. 
In the test staining primary rabbit antibodies (anti-CD80 and anti-iNOS) were detected with 
secondary goat anti-rabbit antibody (1:1000, AlexaFluor® 488 F(ab’) fragment of goat anti-
rabbit IgG (H+L), Invitrogen, Life Technologies, USA). Mouse anti-CD68 antibody in 
combination with rabbit antibodies was detected with secondary goat anti-mouse antibody 
(1:1000, AlexaFluor® 568 F(ab’) fragment of goat anti-mouse IgG (H+L), Invitrogen, Life 
Technologies, USA). In a triple staining with mouse anti-CD68 IgG1 antibody, mouse anti-
HLA-DR IgG2b antibody and rabbit anti-MSR1 the primary antibodies were detected with the 
secondary antibodies, goat anti-mouse IgG1 (1:1000, AlexaFluor® 568 goat anti-mouse IgG1 
(γ1), Invitrogen, Life Technologies, USA), goat anti-mouse IgG2b (1:1000, AlexaFluor® 647 
goat anti-mouse IgG2b (γ2b), Invitrogen, Life Technologies, USA) and goat anti-rabbit (1:1000, 
AlexaFluor® 488 F(ab’) fragment of goat anti-rabbit IgG (H+L), Invitrogen, Life Technologies, 
USA), respectively. Immunofluorescent staining procedures were performed as described 
above. 
 
2.9 Image digitalization 
The stained WTS and TMA slides were digitalized with the TissueFAXS system (version 
2.0.4.0147, TissueGnostics, Austria) using an x20 objective lens. The images had 1392x1024 
pixels (96 DPI, 24 bit color) per field of view (FOV). For the WTSs the whole tumor tissue was 
scanned ranging from 300 to 1500 FOVs (corresponding to approximately 100 to 500 mm²).  
The slides from the immunofluorescent test staining were analyzed with a Zeiss laser 
scanning microscope LSM 700 (Carl Zeiss AG, Germany) using an x40 objective lens. The 
images had 1024x1024 pixels (96 DPI, 24 bit color) per FOV. 
 
2.10 Quantification of the immunohistochemical staining using HistoQuest 
All sections were coded and analyzed by observers blinded for the clinical data. 
The HistoQuest software (version 3.0.3.0161, TissueGnostics, Austria) was used for the 
detection and quantification of the immunohistochemically stained CD8+, CD68+ and CD45+ 
cells. For CD8, two regions were analyzed in each TMA core: i) a 0.78 mm² region of interest 
(ROI) comprising the whole TMA core without discriminating between cancer epithelium and 
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adjacent stromal areas (CD8 whole core) and ii) a ROI of all cancer epithelium within the TMA 
core, comprising mainly tumor cells and only small inclusions of stromal areas within the 
tumor cells, varying in size according to the amount of cancer epithelium (CD8 cancer 
epithelium). As the CD8 whole core and CD8 cancer epithelium data correlated highly (see 
3.3.1) and resulted in very similar prognostic values in survival analyses (see 3.3.6), for CD68 
and CD45 only a 0.78 mm² area comprising the whole core was analyzed. 
 
Using the HistoQuest software, two markers were created for each staining: DAB as 
master marker (CD8, CD68 and CD45, respectively) and hematoxylin as non-master marker 
(nucleus). Each DAB master marker profile was generated optimizing options such as color 
picker, single reference shade, intensity, merging rules and compactness. For the assessment of 
positive cells scattergrams were created for each ROI allowing the visualization and control of 
corresponding positive cells in the source ROI using the backward connection feature. To 
correct false events, specific gates according to cell size and intensity of staining were defined 
and applied to all analyzed samples. Positive cells were quantified according to the selected 
marker and gate. Representative examples for CD8+, CD68+ and CD45+ cell detection with 
HistoQuest is shown in Figure 4. For each patient the CD8+ cell densities (cells/mm²) in the 
whole core and cancer epithelium were obtained as well as the cell densities of CD68+ and 
CD45+ cells in the whole core. 
 
Figure 4. Representative example of immunohistochemically stained CD8+, CD68+ and CD45+ cells in epithelial 
ovarian cancer detected with the HistoQuest software using the backward connection feature; A CD8; B CD68; C CD45; 
optical magnification x200; images acquired with the TissueFAXS/HistoQuest system. 
 
Scoring of the Ki67 was performed manually by two independent observers determining 
the labeling index defined as percentage of positively labeled tumor cells of the total tumor 
cells. 
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2.11 Quantification of the immunofluorescent staining using TissueQuest  
All sections were coded and analyzed by observers blinded for the clinical data. 
The TissueQuest software (version 3.0.0138, TissueGnostics, Austria) was used for the 
detection and quantification of the immunofluorescent CD68 MSR1 double staining. Eight 
FOVs per WTS comprising mainly cancer epithelium were analyzed corresponding to 
approximately 2.7 mm².  
Using the TissueQuest software, three markers were created: DAPI as master marker 
(nucleus), Alexa568 (CD68) and Alexa647 (MSR1) as non-master markers. The parameters 
nuclei size, discrimination by area and discrimination by grey for the nuclear marker and the 
ring mask parameters interior radius and exterior radius for CD68 and MSR1 were adjusted to 
achieve optimal cell detection. For the assessment of positive cells scattergrams were created 
for each FOV, allowing the visualization of corresponding positive cells in the source ROI 
using the real-time back gating feature. To correct false events, specific gates according to cell 
size and intensity of staining were defined and applied to all analyzed samples. Positive cells 
were quantified according to the selected marker and gate. The percentage of CD68+ cells of 
the total cells (DAPI positive) (CD68+/DAPI) and the percentage of double positive 
MSR1+CD68+ cells of total CD68+ cells (MSR1+CD68+/CD68+) was obtained for each 
patient. 
 
2.12 Evaluation and statistical analyses 
Statistical analyses were performed with the SPSS software (version 19, SPSS, Chicago, 
USA) and R (version 1.14). 
 
Blood cell signatures: To obtain complete data sets, gene expressions below the  
RT-qPCR detection sensitivity were imputed using the minimum of the gene expression values 
of the respective assay and fraction of all patients and subtracting it by 1. 
 
Diagnostic 13 gene panel: Significant up- and down-regulations of gene expression of 
the diagnostic 13 gene panel in the seven fractions (HD, CD3, CD14, CD15, CD19, CD25 and 
CD44) between the means of the three patient groups comprising EOC patients (OC group), 
patients with other predominantly malignant diseases except ovarian cancer (M group) and 
controls (B group) were assessed by analysis of variance (ANOVA) followed by correction for 
multiple testing with the Bonferroni testing and the Holm-Bonferroni method. ANOVA was 
2 Materials and Methods 
30 
 
also used to compare the relative risk values of EOC of the combined diagnostic model 
between the patient groups. The relative risk of EOC is a linear combination of the single 
expression values with coefficients listed in Table 1. 
 
Principal Component Analysis (PCA): PCA was performed to assess the influence of 
the two gene panels on the clustering of the analyzed blood cell fractions including the 20 gene 
expressions (13 genes of the diagnostic panel and seven genes of the prognostic panel) as 
variables. PCs of the mean-centered and scaled gene expression values were calculated and the 
first three of them were illustrated with the Eigenvectors with R. 
 
Tumor microenvironment: 
IHC: For the statistical analyses raw CD8+ (determined in the TMA whole core and in 
cancer epithelium), CD68+ and CD45+ cell density values (both determined in the TMA whole 
core) were log2-transformed to achieve an approximately normal distribution. The mean values 
of the two cores were calculated for CD8, CD68, CD45 and Ki67 for each patient. 
IF: The 19 patients were dichotomized into PC1_low and PC1_high with the cut-off 
values at the median. 
 
Correlations: Correlation of continuous variables with approximately normal 
distribution (CD8+ cell density in whole core and cancer epithelium, CD68+ cell density, 
CD45+ cell density, percentage of Ki67+ tumor cells, CD8 relative expression values, PC1, 
PC2 and age) was assessed by Pearson’s correlation coefficients. Correlation of continuous 
non-normally distributed variables (CD68+/DAPI and MSR1+CD68+/CD68+) was assessed by 
Spearman’s correlation coefficients. Continuous variables with approximately normal 
distribution were compared between groups by ANOVA and T-test as appropriate. Continuous 
non-normally distributed variables were compared between two-categorized groups by Mann-
Whitney-U-test. Categorized variables were immune cell clusters (present, absent), FIGO stage 
(II, III, IV), grade (1, 2, 3), histology (serous, non-serous), residual tumor (yes, no) and PC1 
(PC1_low, PC1_high). The association of categorical variables was evaluated by Chi square 
and by Fisher’s exact tests as appropriate. The Holm-Bonferroni method was used to correct for 
multiple testing. 
 
Survival: Univariate and multivariable Cox proportional hazards regression analyses 
were used to evaluate the marginal and adjusted associations of CD8+ (whole core and cancer 
epithelium), CD68+ and CD45+ cell density, percentage of Ki67+ tumor cells, immune cell 
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clusters, CD8 relative expression values and the clinicopathological factors age, histology, 
FIGO stage and residual tumor with survival (Cox, 1972). For multivariable survival analyses, 
the multivariable fractional polynomial approach was used to evaluate possible non-linear 
effects of the continuous variables CD8+ (whole core and cancer epithelium), CD68+ and 
CD45+ cell density, percentage of Ki67+ tumor cells, CD8 relative expression values and age 
on survival by a set of parsimonious transformations (Royston and Sauerbrei, 2008). For  
non-linear associations of the assessed factors with survival, the respective factors were 
transformed according to the shape of non-linearity. Because of the relatively low number of 
outcome events (58), FIGO stage was modeled as an ordinal rather than a categorical variable, 
assuming the same hazard ratio (HR) between FIGO IV and III as between FIGO III and II. 
This strategy saves one degree of freedom and hence provides more stable results than with 
categorical modeling of FIGO stage. Pairwise interactions between variables were tested by 
assessing significance of corresponding product terms. Backward stepwise exclusion of factors 
with inclusion criterion of p≤0.05 and exclusion criterion of p≥0.10 was applied for 
multivariable analyses. 
Cumulative survival probabilities were calculated by the Kaplan-Meier method and the 
log-rank test. The study population was dichotomized into CD45_low and CD45_high, 
CD8_low and CD8_high and into Ki67_low and Ki67_high with the cut-off values at the 
respective medians as well as into Ki67- and Ki67+ with the cut-off value according to the 
shape of the non-linearity. 
Two-sided p values <0.05 were considered statistically significant in all analyses. 
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3 Results 
3.1 Study population and patients’ material 
Blood cell signatures: A total of 23 women were included in the blood cell signature 
study whose clinical and pathological characteristics are summarized in Table 4. 
 
Table 4. Characteristics of the blood cell signature cohort. 
Patient groups N (%) Characteristics 
Relative risk 
of EOC* 
Ovarian cancer N = 4  Histology FIGO Grade 
 
EOC 4 (100.0) 
serous I 2 2.9 
serous III 3 3.5 
mucinous III 2 7.5 
undifferentiated III 3 3.5 
Other malignancies except ovarian cancer N = 6   Histology   
 
Krukenberg tumor 2 (33.3) adenocarcinoma 
  2.5 
  2.9 
Signet ring cell carcinoma 1 (16.7) adenocarcinoma with signet ring cells   3.6 
Borderline tumor 1 (16.7) serous cystadenoma, borderline morphology   4.8 
Lymphoma 1 (16.7) follicular lymphoma   5.7 
Teratoma 1 (16.7) dermoid cyst   0.3 
Benign diseases and healthy individuals N = 13 
 
Hypermenorrhea 1 (7.7)    -4.9 
Fibroma 1 (7.7)    -2.0 
Myoma 2 (15.4) 
   -1.4 
   2.2 
CIN I, HPV-HR positive 3 (23.1) 
   -3.9 
   -2.7 
   1.5 
CIN II, HPV-HR positive 1 (7.7)    1.5 
CIN II, HPV-HR negative 1 (7.7)    4.3 
Abortion 1 (7.7)    -6.6 
Healthy individuals 3 (23.1) 
   -2.0 
   -1.8 
   -0.8 
EOC: epithelial ovarian cancer; CIN: cervical intraepithelial neoplasia; HPV-HR: human papilloma virus – high risk 
* The relative risk of EOC is a linear combination of the gene expression values of the diagnostic gene panel with coefficients listed in 
Table 1. The gene expressions were assessed in the “high density” blood leukocyte fraction. 
 
In the group of ten patients with suspected EOC only four patients were finally diagnosed 
with EOC (OC group). Six patients had other predominantly malignant diseases including 
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Krukenberg tumor, signet ring cell carcinoma, borderline tumor, lymphoma and teratoma. They 
were summarized in a separate patient group (M group). The control group comprised three 
healthy blood donors and ten patients with benign gynecological diseases such as 
hypermenorrhea, myoma, fibroma and cervical intraepithelial neoplasia (CIN) (B group). 
For each woman the relative risk values of EOC according to the diagnostic gene panel 
assessed in the HD fraction are given in Table 4. 
 
In the microscopic examination of the blood samples that had been incubated 
simultaneously with two types of antibodies coupled to different sized beads no double binding 
of different bead-linked antibodies to the same cell was observed. 
 
Tumor microenvironment: Clinical and pathological characteristics of the tumor samples 
of the 209 patients included in the immunohistochemical analysis of tumor proliferation and 
leukocyte infiltration and of the tumor samples of the 19 patients selected for the 
immunofluorescent analysis of TAMs are depicted in Table 5. Patients predominantly 
presented with cancer at advanced stages (96% and 84% FIGO III/IV in the 209 and in the 19 
patient cohort, respectively) and of serous histology (88% and 79%, respectively). 
 
Table 5. Characteristics of EOC of the tumor microenvironment cohort. 
 N = 209 N = 19 
Characteristics N (%) N (%) 
Histology   
Serous 184 (88.0) 15 (78.9) 
Non-serous 25* (12.0) 4** (21.1) 
FIGO   
FIGO II 9 (4.3) 3 (15.8) 
FIGO III 164 (78.5) 13 (68.4) 
FIGO IV 36 (17.2) 3 (15.8) 
Grade    
Grade 1 9 (4.3)  
Grade 2 46 (22.0) 4 (21.1) 
Grade 3 153 (73.2) 15 (78.9) 
unknown 1 (0.5)  
Residual tumor   
no 146 (69.9) 8 (42.1) 
yes 63 (30.1) 11 (67.9) 
* Endometrioid, 9; Mixed epithelial, 9; Mucinous, 1; Undifferentiated carcinoma, 4; Clear cell carcinoma, 2; 
** Endometrioid, 2; Mixed epithelial, 2; 
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The median age of the 209 patient cohort and of the 19 patient cohort was 56 years (range 
18-85 years) and 58 years (range 18-81 years), respectively. 22 patients out of the 209 patients 
(11%) had refractory disease. These patients were excluded for PFS analyses since the exact 
time point of progression of disease could not be determined. The median PFS was 18 months 
(range 6-48 months) and 13 months (range 5-41 months) in the 209 patient cohort and in the 19 
patient cohort, respectively; the median OS was 24 months (range 1-49 months) and 21 months 
(range 5-41 months), respectively. The follow-up time ranged from 1 to 49 months with a 
median of 30 months in the 209 patient cohort and ranged from 5 to 41 months with a median 
of 28 months in the 19 patient cohort. 58 out of the 209 patients (28%) and 4 out of the 19 
patients (21%) died within the observation period. 
 
3.2 Blood cell gene signatures 
3.2.1 Diagnostic panel: heterogeneous expressions and significant differences between 
patient groups 
The gene expression patterns of the diagnostic 13 gene panel comprising CFP, NOXA1, 
NEAT1, BC037918, DIS3, ZNF419, CCR2, B4GALT1, PAPOLG, PRIC285, AP2A1, C1orf63 
and OSM in the seven fractions, HD, CD3, CD14, CD15, CD19, CD25 and CD44, did not 
reveal a single blood cell fraction obviously suitable for the determination of this signature. The 
comparison of the assessed expression values in the seven fractions between individuals 
showed similar expression patterns among individuals for most genes (data not shown). Most 
genes were differently expressed in the analyzed blood cell fractions and/or showed different 
expression patterns according to the three patient groups, EOC patients (OC group), patients 
with other predominantly malignant diseases except ovarian cancer (M group) and controls 
comprising patients with benign diseases and healthy individuals (B group) (Figure 5). These 
similar patterns among individuals indicate that these genes are partially differentially 
expressed depending on the cell type and/or on the patient group, but fairly independent of the 
individual. 
CFP, AP2A1 and NEAT had the expression peaks in the fractions CD25 and CD15. The 
latter two genes showed differences between patient groups in many fractions. BC037918 had 
the highest expression values in the fractions HD and CD15 with several patient group specific 
differences. OSM showed expression differences among fractions with the highest value for 
fraction CD15, but equal expression patterns in the different patient groups. 
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Figure 5. Star plots of the expression values of the 13 genes of the diagnostic panel (A – M) in the assessed blood cell 
fractions. The colors represent the patient groups: green – benign diseases, blue – malignant diseases except ovarian 
cancer, red – ovarian cancer; HD: high density. The mean expression values are shown as continuous lines. The standard 
deviations are shown as dashed lines. 
 
DIS3, B4GALT1, PAPOLG and C1orf63 were characterized by similar expression levels 
without characteristic peaks in the different blood cell fractions. Patient group specific 
expressions were rare in these four genes, except for PAPOLG. Similarly, PRIC285 showed 
uniform expression among fractions and patient groups with the exception of slightly higher 
expression values in fraction CD15 of all three patient groups and higher expression values in 
fraction CD25 of the patient group OC. CCR2 and NOXA1 were both highest expressed in 
fraction CD14 followed by the fractions CD25 and CD44, whereby CCR2 additionally showed 
patient group specific differences. ZNF419 did not show a clear pattern, but was characterized 
by high standard deviations due to high variations between individuals. 
Six of the 13 genes from the diagnostic panel had the expression peaks in the fractions of 
CD15+, CD25+ and CD44+ enriched cells: CFP, NEAT1, BC037918, PRIC285, AP2A1 and 
OSM. In contrast, the genes NOXA1 and CCR2 presented a similar expression pattern to most 
genes of the prognostic panel with the highest expression values in the fractions of CD14+ and 
CD25+ enriched cells. DIS3, B4GALT, PAPOLG and C1orf63 were characterized by equal 
expression values in the different fractions. ZNF419 did not show any characteristic pattern. 
 
ANOVA comparing the mean expression values of the 13 genes in the seven fractions 
between the three patient groups OC, M and B and subsequent Bonferroni correction revealed 
31 significantly different gene expressions; the more stringent Holm-Bonferroni method 
revealed 21 significantly different gene expressions. Table 6 shows the mean gene expression 
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values of the 13 genes in the seven blood cell fractions and significant up- and down-
regulations comparing the three patient groups. Figure 6 exemplarily depicts gene expression 
box plots of significantly differentially expressed genes among the patient groups in the 
respective fractions. Significant differences were mostly revealed between the control group B 
and the two malignant groups M and OC, whereas few significant differences were exclusively 
found between group OC and group B (CCR2 in fraction CD14, NEAT1 in fraction CD25 and 
DIS3 in fraction CD44). The genes NEAT1, AP2A1 and PAPOLG were characterized by most 
patient group specific expressions. The fractions with most gene expression differences 
between patient groups were the fractions CD19 and CD3 corresponding to the lymphocyte 
fractions (CD19 representing the B cell fraction and CD3 representing the T cell fraction) and 
the fraction CD44 (representing a mixture of tissue cells, erythrocytes and leukocytes). 
Interestingly, the fractions CD3 and CD19 were characterized by generally low expression 
values for the genes of the diagnostic panel. In contrast, the fractions CD15, CD25, CD14 and 
HD with higher expression values showed no (CD15) or fewer patient group specific gene 
expressions. 
 
 
 
A. High density fraction. 
 
  
Table 6. Comparison of gene expression values of the 13 genes of the diagnostic 
panel between the patient groups with benign diseases (B), malignant diseases 
except ovarian cancer (M) and ovarian cancer (OC) in the seven blood cell 
fractions (A - G). 
HD: high density 
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B. CD3+ enriched cells. 
 
 
C. CD14+ enriched cells. 
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D. CD15+ enriched cells. 
 
 
E. CD19+ enriched cells. 
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F. CD25+ enriched cells. 
 
 
 
G. CD44+ enriched cells. 
 
 
 
 
 
Figure 6. Examples of expression box plots 
of significantly differently expressed genes 
of the diagnostic gene panel among the 
patient groups in the assessed blood cell 
fractions (A - G). Colors represent the 
patient groups: green - benign diseases (B), 
blue - malignant diseases except ovarian 
cancer (M), red - ovarian cancer (OC).  
Significant up- and down-regulations of gene expressions assessed by ANOVA 
and Bonferroni testing (significant pairs in bold, key of the smaller patient group 
under the patient group with the larger mean) and by Holm-Bonferroni testing 
(significance marked with a star) 
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The relative risk of EOC according to the diagnostic 13 gene panel was computed for each 
patient for all seven blood cell fractions. The comparison of the relative risk values between the 
three patient groups assessed in the HD fraction revealed significantly higher values in the two 
malignant groups OC and M than in the benign group B (Table 7 and Figure 7). The relative 
risk values of each woman included in the study determined in the HD fraction is listed in 
Table 4. A trend of higher relative risk values in the OC group compared to the M group was 
observed which was, however, not significant. In the control group relative risk values of EOC 
were lower, with the exception of one outlier with a relative risk value of 4.2 that was in the 
order of the relative risk values in the group OC (mean 4.4) and in the group M (mean 3.3). 
This woman was 28 years old, diagnosed with CIN II and human papilloma virus – high risk 
(HPV-HR) negative. She did not present with any histological signs of malignancy. The 
relative risk values of EOC of the other four CIN patients who were all HPV-HR positive were 
equal or below the 75th percentile of the control group. 
Only the expression values obtained from the HD fraction resulted in significantly different 
relative risk values between the malignant and the benign patient groups, whereas in the other 
fractions no differences between the patient groups were found with the formula of relative risk 
of EOC developed for the HD fraction (data not shown).  
 
 
 
 
 
 
 
Significant differences assessed by ANOVA (significant pairs in bold, key of 
the smaller patient group under the patient group with the larger mean) 
 Figure 7. Box plots of relative risk values of ovarian 
cancer in patients with benign diseases (B), malignant 
diseases except ovarian cancer (M) and ovarian 
cancer (OC) according to the diagnostic 13 gene 
panel assessed in the high density fraction. 
Table 7. Mean of relative risk values of ovarian cancer in patients 
with benign diseases (B), malignant diseases except ovarian cancer 
(M) and ovarian cancer (OC) according to the diagnostic 13 gene 
panel assessed in the high density fraction. 
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3.2.2 Prognostic panel: peaks in the fractions CD14 and CD25 
The analysis of the gene expression patterns of the prognostic seven gene panel 
comprising SRC, GUCY1B3, TUBB1, GUCY1A3, TUBA8, EGF and TRIM14 in the seven 
blood cell fractions showed a similar expression pattern for most genes with peaks in the 
fractions of CD14+ and CD25+ enriched cells and the lowest values in the fraction of CD3+ 
enriched cells. This expression pattern was similar to the expression patterns of NOXA1 and 
CCR2 of the diagnostic panel. Figure 8 exemplarily depicts star plots of two genes showing the 
described expression pattern. SRC, GUCY1B3, TUBB1, GUCY1A and EGF were highest 
expressed in the fractions CD14 and CD25. GUCY1B3, TUBB1 and GUCY1A additionally 
showed expression peaks in the fraction of CD44+ enriched cells. In contrast, TUBA8 and 
TRIM14 were characterized by similar expression levels without characteristic peaks in the 
different blood cell fractions. 
 
 
Figure 8. Star plots of the expression values of A SRC and B GUCY1A3 of the prognostic gene panel in the assessed 
blood cell fractions showing similar expression patterns. The colors represent the patient groups: green – benign diseases, 
blue – malignant diseases except ovarian cancer, red – ovarian cancer; HD: high density. The mean expression values are 
shown as continuous lines. The standard deviations are shown as dashed lines. 
 
Gene expression differences between EOC patients with favorable prognosis and those 
with a worse clinical outcome were not assessed since the number of patients was far too low 
and at the time of analysis follow-up time was only several months which was not sufficient for 
analysis of the clinical outcome. 
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3.2.3 Principal Component Analysis of expression patterns in the blood fractions 
To reduce the complexity of the gene expression data sets of the genes of the diagnostic 
and the prognostic gene panel, PCA was performed with the 20 genes as variables. The genes 
of the two different panels were combined in the PCA to include as many expression data as 
available for the determination of differences and similarities between the different blood cell 
fractions.  
Using the first three PCs, clustering of the fractions of the patient groups B, M and OC 
and the influences of the gene expressions of the prognostic seven gene panel and the 
diagnostic 13 gene panel was examined (Figure 9). The importance of the 20 PCs regarding 
proportion of data variance are presented in Figure 9A. 
Figure 9B depicts the first two PCs and shows four clusters of fractions: i) HD and 
CD15, ii) CD3 and CD19, iii) CD14 and CD25 and iv) CD25_OC as an outlier far apart from 
all other fractions. The fractions of CD44+ enriched cells of the three patient groups were 
localized in the center of the biplot between the three clusters. 
Regarding clustering of gene expression values and associated blood cell fractions three 
clusters were obvious: i) most of the genes from the diagnostic panel (CFP, NEAT1, 
BC037918, B4GALT1, PAPOLG, PRIC285, AP2A1, C1orf63 and OSM) with the fractions 
HD and CD15, ii) DIS3 and ZNF419 from the diagnostic panel and TRIM14 from the 
prognostic panel with the fractions CD3 and CD19 and iii) most of the genes from the 
prognostic panel (SRC, GUCY1B3, TUBA8, TUBB1, GUCY1A3 and EGF) and NOXA1 and 
CCR2 from the diagnostic panel with the fractions CD14 and CD25. 
The clusters revealed by PCA are in accordance with the expression patterns of the 20 
genes in the different blood cell fractions (Figure 4 and 7), which also indicated similarities 
between most genes of the prognostic panel and NOXA1 and CCR2 of the diagnostic panel. 
Moreover, DIS3, ZNF419 and TRIM14 were already shown to have differing expression 
patterns compared to most other genes of the two panels. 
The comparison of the blood cell fractions between the different patient groups showed 
only marginal differences between the three patient groups in the fractions CD14, CD15 and 
CD19. In contrast, there were substantial differences between the patient groups OC/M and B 
in the fractions CD44, CD3 and HD. The fraction CD25 showed the greatest difference 
between the patient group OC in comparison to the patient groups M and B. 
 
 
     3 Results 
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Results 
46 
 
 
Figure 9. Principal component analysis (PCA) using the prognostic seven gene panel (d1-7: SRC, GUCY1B3, TUBA8, 
TUBB1, GUCY1A1, EGF and TRIM14) and the diagnostic 13 gene panel (p1-13: CFP, NOXA1, NEAT1, BC037918, 
DIS3, ZNF419, LCCR2, B4GALT1, PAPOLG, PRIC285, AP2A1, C1orf63 and OSM) as variables (blue vectors) for the 
assessment of clustering of the fractions of the patient groups (benign diseases (B), malignant diseases except ovarian 
cancer (M) and ovarian cancer (OC)) ; HD: high density. A Importance of the 20 PCs regarding proportion of data 
variance. A proportion of variance of 0.76 were covered by PC1 (0.33), PC2 (0.31) and PC3 (0.12). B PC1 and PC2 show 
four clusters of fractions (marked in red): i) HD and CD15, ii) CD3 and CD19, iii) CD14 and CD25 and iv) CD25_OC. C 
PC2 and PC3 reveal three clusters (marked in red): i) HD and CD15, ii) CD3, CD14, CD19, CD44, CD25_M/B and iii) 
CD25_OC. 
 
Figure 9C depicting the second and the third PCs showed similar clusters: i) HD and 
CD15, ii) CD3, CD14, CD19, CD44, CD25_M and CD25_B and iii) CD25_OC. 
As in Figure 9B most of the genes from the diagnostic panel clustered with the fractions 
HD and CD15. All genes from the prognostic panel and NOXA1 and CCR2 from the 
diagnostic panel clustered with the fractions CD3, CD14, CD19, CD44, CD25_M and 
CD25_B. In contrast to Figure 9B, Figure 9C showed more discriminative power between the 
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patient groups: The biggest differences were revealed for CD25 where the three patient groups 
were distributed all over the plot. Smaller, but substantial differences were found for the 
fractions CD15, CD3 and CD19, whereby the patient groups OC and M clustered closer 
together than patient group B. 
 
3.3 Tumor microenvironment 
3.3.1 Immunohistochemical staining 
CD8, CD68, CD45 and Ki67 immunohistochemical stainings were performed with tumor 
tissues of the 209 EOC patients assembled on TMAs. In Figure 10 staining of the four markers 
are depicted for one exemplary TMA core. Tumor infiltrating leukocytes were observed in the 
cancer epithelium as well as in the stromal areas (Figure 10). 
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Figure 10. Representative example of the CD8, CD68, CD45 and Ki67 immunohistochemical staining of the same tissue 
microarray core of epithelial ovarian cancer of serous histology; A CD8; B CD68; C CD45; D Ki67; optical magnification 
x200; images acquired with the TissueFAXS/HistoQuest system. 
 
In about 10% of the tumor tissue samples CD8+, CD68+ and/or CD45+ cells clustered 
together forming leukocyte aggregates (Figure 11). The number and size of aggregates per core 
varied among the tumor samples from only one cluster of about 50 µm in diameter to more than 
ten clusters of more than 300 µm in diameter. The aggregates were characterized by high 
densities of cells with a small, round and regular nucleus and a relatively small cytoplasm. In 
some cases they comprised almost exclusively one cell type (CD8+ or CD68+ cells); in other 
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samples clusters contained cells positive for all the assessed leukocyte markers as well as 
marker negative cells (Figure 11A). 
 
 
Figure 11. Immune cell clusters in epithelial ovarian cancer tissue. A CD8; B CD68; C CD45; optical magnification x200; 
images acquired with the TissueFAXS/HistoQuest system. 
 
The density of infiltrating immune cells was wide ranging from marginal to about  
2,000 cells/mm². Figure 12 shows pictures of representative specimens characterized by a high 
and low infiltration of CD8+, CD68+ and CD45+ cells as well as a high and low Ki67 labeling 
index. 
Of the 209 patients included in the study IHC data for 190 to 207 patients – dependent on 
the marker – could be obtained since some of the cores were not evaluable (see 4.2.8). The 
percentage of tumor tissue present in the cores varied from 30% to 100% with a median of 65% 
corresponding to an area of approximately 0.65 mm². 
CD8 analysis could be performed with 207 samples. CD8+ cells were present in all 
analyzed samples. CD8+ cells ranged from 1 to 1,931 cells/mm2 with a median of  
126 cells/mm2 in the whole core (CD8 whole core) and from 3 to 2,257 cells/mm2 with a 
median of 137 cells/mm2 in the cancer epithelium (CD8 cancer epithelium), respectively. CD8 
whole core, comprising the whole TMA core with cancer epithelium as well as adjacent stromal 
areas, and CD8 cancer epithelium, comprising almost exclusively tumor cells, correlated 
strongly with each other (p=0.95, p<0.001). Similarly, almost identical correlation coefficients 
with the other biological markers (data not shown) and HRs in survival analyses (see 3.3.6) 
were obtained for CD8 whole core and CD8 cancer epithelium. Therefore CD68+ and CD45+ 
cells were solely analyzed in the whole core. CD68+ cell infiltration could be assessed in 199 
patient samples and ranged from 0 to 1,615 cells/mm² with a median of 277 cells/mm² in the 
whole core. For 190 samples CD45+ cell infiltration could be determined and ranged from 12 
to 2,514 cells/mm² with a median of 378 cells/mm² in the whole core. As expected, CD45+ 
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cells comprising all leukocytes showed higher values than the more specific leukocyte 
populations of CD8+ and CD68+ cells. The Ki67 labeling index could be analyzed in 203 
samples and ranged from 0% to 90% with a median of 30%. Log2-transformed CD8+, CD68+ 
and CD45+ values showed an acceptable standard distribution. 
 
Figure 12. Representative epithelial ovarian cancer tissues characterized by high and low infiltration of CD8+ (A, B, C), 
CD68+ (D, E, F) and CD45+ (G, H, I) cells as well as high and low Ki67 labeling index (J, K, L); A, B, D, E, G, H, J 
and K high infiltration and labeling index, respectively; C, F, I and L low infiltration and labeling index, respectively; 
optical magnification x200; images acquired with the TissueFAXS/HistoQuest system. 
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Table 8 summarizes the correlation coefficients between the densities of CD8+, CD68+ and 
CD45+ cells in the whole core and the Ki67+ labeling index. Numbers of CD45+ cells 
correlated moderately with those of CD8+ and CD68+ cells, while CD8+ and CD68+ data did 
not correlate with each other. As expected, a positive correlation between the presence of 
immune cell clusters and tumor infiltration of CD8+, CD68+ and CD45+ cells was found 
(p<0.001, p=0.010 and p<0.001, respectively). The percentage of Ki67+ tumor cells did not 
correlate with the infiltration of CD8+, CD68+ or CD45+ cells or the presence of immune cell 
clusters. 
 
Table 8. Cell densities of CD8+, CD68+, CD45+ cells (cells/mm²) in the whole core and Ki67 labeling index with 
pairwise correlation coefficients (R). 
 Cell densities and labeling index 
  Correlations   
 CD8 CD68 CD45 Ki67 
CD8 
Range cells/mm² 
Median cells/mm² 
N 
1-1931 
126 
207 
R 
p 
adjusted p * 
N 
 
0.353P 
≤ 0.001 
≤ 0.001 
199 
0.709P 
≤ 0.001 
≤ 0.001 
189 
-0.083P 
0.239 
 
201 
CD68 
Range cells/mm² 
Median cells/mm² 
N 
0-1615 
277 
199 
R 
p 
adjusted p * 
N 
 
 
0.578P 
≤ 0.001 
≤ 0.001 
186 
0.192P 
0.007 
0.028 
196 
CD45 
Range cells/mm² 
Median cells/mm² 
N 
12-2514 
378 
190 
R 
p 
adjusted p * 
N 
   
0.053P 
0.471 
 
187 
Ki67 
Range % 
Median % 
N 
0-90 
30 
203 
 
 
 
 
   
 
 
P correlation assessed with Pearson method 
* adjusted p: significant p values were corrected for multiple testing with the Holm-Bonferroni method 
 
3.3.2 Immunofluorescent staining 
Immunofluorescent double staining with CD68 and MSR1 was performed with tumor 
tissues of 19 patients on WTSs (Figure 13). TAMs were observed within tumor cells and in the 
stromal areas (Figure 14). As in the immunohistochemical staining, aggregates of macrophages 
were observed (Figure 14D). The percentage of CD68+ cells of total cells (DAPI positive) 
(CD68+/DAPI) ranged from 1% to 19% with a median of 4.5%. The percentage of double 
positive MSR1+CD68+ cells of total CD68+ cells (MSR1+CD68+/CD68+) ranged from 42% 
to 95% with a median of 83%. CD68+/DAPI and MSR1+CD68+/CD68+ values showed 
bimodal distributions. Figure 14 shows representative tumor tissue specimens characterized by 
high and low infiltration of TAMs as well as high and low percentages of alternatively 
activated macrophages. CD68+/DAPI and MSR1+CD68+/CD68+ showed a weak correlation, 
but significance did not hold after correction for multiple testing (Table 9). 
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Figure 13. Immunofluorescent CD68 MSR1 double staining in epithelial ovarian cancer, DAPI for nuclear 
counterstaining; A three channel overlay: DAPI light grey, CD68 red, MSR1 green; B DAPI; C CD68; D MSR1; optical 
magnification x200; images acquired with the TissueFAXS/TissueQuest system. 
 
Figure 14. Immunofluorescent CD68 (red) MSR1 (green) double staining in epithelial ovarian cancer, DAPI for nuclear 
counterstaining (light grey); three channel overlay; A high macrophage infiltration, ~60% MSR1+CD68+ cells of total 
CD68+ cells (MSR1+CD68+/CD68+); B high macrophages infiltration, >90% MSR1+CD68+/CD68+; C low 
macrophages infiltration, >90% MSR1+CD68+/CD68+; D aggregate of macrophages at tumor border, ~50% 
MSR1+CD68+/CD68+; optical magnification x200; images acquired with the TissueFAXS/TissueQuest system. 
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Table 9. Pairwise correlation coefficients (R) of the percentage of CD68+ cells of total cells (CD68+/DAPI), percentage 
of MSR1+CD68+ cells of total CD68+ cells (MSR1+CD68+/CD68+), PC1 and PC2 from the prognostic seven gene 
panel. 
  CD68+/DAPI MSR1+CD68+/CD68+ PC1 PC2 
CD68+/DAPI 
R 
p 
adjusted p * 
N 
 
0.533S 
0.019 
0.095 
19 
0.396S 
0.093 
 
19 
0.074S 
0.764 
 
19 
MSR1+CD68+/CD68+  
R 
p 
adjusted p * 
N 
  
0.709S 
0.001 
0.006 
19 
0.018S 
0.943 
 
19 
PC1 
R 
p 
adjusted p * 
N 
   
0.162P 
0.507 
 
19 
PC2 
 
 
 
   
 
 
P correlation assessed with Pearson method 
S correlation assessed with Spearman method 
* adjusted p: significant p values were corrected for multiple testing with the Holm-Bonferroni method 
 
 
Figure 15 depicts examples of the test staining performed with potential M1 markers 
(CD80, iNOS and HLA-DR). The used anti-CD80 and anti-iNOS antibodies showed reactivity 
to tumor cells in some EOC tissue samples and were, therefore, not appropriate for detection of 
TAMs in EOC tissue. Triple staining performed with CD68, MSR1 and HLA-DR revealed 
triple positive cells. This observation indicates that M2 polarized macrophages also express 
HLA-DR and that the marker is not specific for M1 macrophages. Due to the unsatisfying 
results these tested markers were not used for further staining. 
 
Figure 15. Immunofluorescent test staining with CD68 and potential M1 markers in epithelial ovarian cancer, DAPI for 
nuclear counterstaining (light grey); A CD68 (red) CD80 (green) double staining showing CD80+ tumor cells; B CD68 
(red) iNOS (green) double staining showing iNOS+ tumor cells; C CD68 (red) MSR1 (green) HLA-DR (blue) triple 
staining showing triple positive cells; optical magnification x400; images acquired with a Zeiss laser scanning microscope 
LSM 700 microscope. 
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3.3.3 Correlation of TAMs and the prognostic blood cell signature 
PC1, a linear combination of the expression values of the prognostic seven gene panel 
associated with reduced OS, correlated with MSR1+CD68+/CD68+ with a Spearman 
Coefficient of 0.71 (p=0.006, Table 9, Figure 16C). When the 19 patient cohort was 
dichotomized into PC1_high and PC1_low at the median of the PC1 values (median 0.18), 
Mann-Whitney-U-test showed that the mean of MSR1+CD68+/CD68+ in the PC1_high group 
was significantly higher than in the PC1_low group (p=0.001, Figure 16B). PC2, a  
PC1-uncorrelated linear combination of the expression values of the prognostic seven gene 
panel and predictive for death within the first two years after EOC diagnosis, did not correlate 
with macrophage cell numbers, neither with CD68+/DAPI nor with MSR1+CD68+/CD68+ 
(Table 9). 
 
 
Figure 16. Association of PC1 and the percentage of MSR1+CD68+ cells of total CD68+ cells (MSR1+CD68+/CD68+). 
A Box plot of the PC1 values of the patient groups PC1_low and PC1_high; B box plot of MSR1+CD68+/CD68+ of 
PC1_low and PC1_high patients showing higher MSR1+CD68+/CD68+ values for PC1_high than for PC1_low patients 
(p=0.001); C scatter plot of MSR1+CD68+/CD68+ and PC1 showing a correlation with a Spearman Coefficient of 0.71 
(p=0.006). 
 
3.3.4 RT-qPCR CD8 relative expression values  
Both mRNA expression data and IHC results could be obtained from 160 patients. No 
correlation between the CD8 gene expression values and the CD8+ density values was found 
(R=0.30, p<0.001). 
 
3.3.5 Correlation with clinicopathological factors 
No associations with the clinicopathological parameters age (continuous), histology 
(serous, non-serous), FIGO stage (II, III, IV), grade (1, 2 and 3) and residual tumor (yes, no) 
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were found for CD8 (whole core and cancer epithelium), CD68, CD45 or Ki67 (data not 
shown). Neither was there an association between immune cell clusters and the 
clinicopathological parameters or between CD8 gene expression values and the 
clinicopathological parameters (data not shown). Except for an expected association between 
FIGO stage and residual tumor (p=0.009), no associations between the assessed 
clinicopathological factors were revealed (data not shown). 
 
3.3.6 Survival analyses 
Fractional polynomial modeling of the continuous factors age, CD8 (whole core and 
cancer epithelium), CD68, CD45 and Ki67 confirmed linearity for age, CD8, CD68 and CD45, 
whereas a non-linear association of Ki67 with survival was revealed. Visualization of the shape 
of this non-linearity showed that the mortality risk was sharply increased for patients with a 
Ki67 labeling index lower than 5%, while it was constantly low for patients with a Ki67 
labeling index greater than 5% (data not shown). Therefore, it seemed reasonable to 
dichotomize Ki67 at a cutoff of 5% resulting in eleven patients with Ki67- tumors (<5% Ki67+ 
tumor cells) and 186 patients with Ki67+ tumors (≥5% Ki67+ tumor cells). No associations 
between the 5%-dichotomized Ki67 variable and the clinicopathological parameters were found 
(data not shown). 
This dichotomization was used for OS and PFS analyses. Figure 17 represents the 
corresponding Kaplan-Meier survival estimates for Ki67 with the cut-off value at 5% (Figure 
17A) and the corresponding estimate for Ki67 with the cut-off at the median (Figure 17B).  
 
 
Figure 17. Kaplan-Meier curves showing the association between Ki67 and patient overall survival. A Ki67 (<5% versus 
≥5%); log-rank test, p = 0.002; B Ki67 (<30% versus ≥30%); log-rank test, p = 0.747. 
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When dichotomized at 5%, patients with Ki67- tumors had dramatically reduced OS 
compared to patients with Ki67+ tumors (log-rank test, p=0.002, Figure 17A), whereas no 
survival advantage can be seen, when dichotomized at the median (log-rank test, p=0.747, 
Figure 17B). Correlation of Ki67 (<5% versus ≥5%) and refractory disease showed that 
patients with Ki67- tumors were over-represented in the patient group who suffered from 
refractory disease (24%) compared to patients with Ki67- tumors in the remaining group of 
patients (3%) (log-rank test, p=0.003). 
 
Multivariable Cox proportional hazards regression analyses including the 
clinicopathological factors age, histology, FIGO stage and residual tumor after cytoreductive 
surgery and the immunohistochemical data for CD8 (separate analysis of CD8 whole core and 
CD8 cancer epithelium), CD68, CD45 and the percentage of Ki67+ tumor cells (<5% versus 
≥5%) revealed age, FIGO stage, CD45 and Ki67 to be significantly and independently 
associated with survival. In contrast, histology, residual tumor, CD8 (whole core and cancer 
epithelium) and CD68 did not have any prognostic impact on OS. While the mortality risk 
increased slightly per each ten years of age (per decade: HR=1.02, 95% confidence interval 
(CI) 1.00-1.05), it was doubled if the patients had a higher FIGO stage (IV versus III or III 
versus II: HR=2.09, 95% CI 1.14-3.83). Mortality risk reduced by approximately 16% with 
each doubling of CD45+ cell density (HR=0.84, 95%CI 0.71-1.00). Moreover, patients with 
Ki67- tumors (<5% Ki67+ tumor cells) had a significantly poorer OS than those with Ki67+ 
tumors (≥5% Ki67+ tumor cells) (HR 3.26, 95%CI 1.43-7.45, Table 10). Univariate analysis 
showed age, FIGO stage, residual tumor, CD45 and Ki67 to be associated with OS (Table 10). 
 
For PFS, FIGO stage, residual tumor and CD45 were shown to be independent 
prognostic factors. Similarly to OS analysis, higher FIGO stage corresponded with a more than 
doubling of risk for recurrent disease (IV vs. III, III vs. II: HR=2.44, 95%CI 1.55-3.85). 
Patients with residual tumor after surgery had a 70% increased risk (HR=1.70, 95%CI  
1.08-2.65). A doubling of CD45+ cell density reduced the risk for disease progression by 
approximately 13% (HR=0.87, 95%CI 0.76-0.99, Table 11). Univariate analysis showed age, 
FIGO stage and residual tumor to be associated with OS (Table 11). 
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Table 10. Prognostic significance of clinicopathological parameters, CD8, CD68, CD45 and Ki67 in univariate and 
multivariable overall survival analysis. 
Overall survival 
N = 209 Univariate Multivariable 
Characteristics HR (CI95%) p HR (CI95%) p 
Age (continuous, per decade) 1.04 (1.01-1.06) 0.001 1.02 (1.00-1.05) 0.044 
Histology (non-serous vs. serous) 1.15 (0.55-2.43) 0.713 *  
FIGO (ordinal, per stage) 1.90 (1.10-3.30) 0.022 2.09 (1.14-3.83) 0.018 
Residual tumor (yes vs. no) 1.89 (1.12-3.21) 0.018 *  
CD8 whole core° (continuous, per doubling) 0.88 (0.76-1.02) 0.081 *  
CD8 cancer epithelium° (continuous, per doubling) 0.88 (0.77-1.01) 0.077 *  
CD68 (continuous, per doubling) 0.95 (0.83-1.10) 0.493 *  
CD45 (continuous, per doubling) 0.82 (0.70-0.96) 0.013 0.84 (0.71-1.00) 0.043 
Ki67 (<5% vs. ≥5%) 3.23 (1.46-7.16) 0.004 3.26 (1.43-7.45) 0.005 
HR: Hazard Ratio; CI: Confidence Interval; ° separate analysis of CD8 whole core and CD8 cancer epithelium 
 
Table 11. Prognostic significance of clinicopathological parameters, CD8, CD68, CD45 and Ki67 in univariate and 
multivariable progression-free survival analysis. 
Progression-free survival 
N = 187 Univariate Multivariable 
Characteristics HR (CI95%) p HR (CI95%) p 
Age (continuous, per decade) 1.02 (1.00-1.03) 0.035 *  
Histology (non-serous vs. serous) 0.97 (0.60-1.55) 0.882 *  
FIGO (ordinal, per stage) 2.46 (1.75-3.46) <0.001 2.44 (1.55-3.85) <0.001 
Residual tumor (yes vs. no) 2.13 (1.52-3.00) <0.001 1.70 (1.08-2.65) 0.021 
CD8 whole core° (continuous, per doubling) 1.01 (0.91-1.11) 0.903 *  
CD8 cancer epithelium° (continuous, per doubling) 1.00 (0.91-1.10) 0.992 *  
CD68 (continuous, per doubling) 0.97 (0.87-1.07) 0.493 *  
CD45 (continuous, per doubling) 0.93 (0.82-1.05) 0.243 0.87 (0.76-0.99) 0.040 
Ki67 (<5% vs. ≥5%) 1.17 (0.43-3.19) 0.753 *  
HR: Hazard Ratio; CI: Confidence Interval; ° separate analysis of CD8 whole core and CD8 cancer epithelium  
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To separately assess the influence of each leukocyte marker on the outcome, 
multivariable Cox proportional hazards regression analyses including only one leukocyte 
marker (CD8, CD68 or CD45), Ki67 and the clinicopathological factors were performed, while 
omitting the other two leukocyte markers. Again, CD8 cancer epithelium and CD8 whole core 
data were separately analyzed. OS analysis with the CD8 intraepithelial data omitting the 
markers CD68 and CD45 revealed age (HR=1.03, 95%CI 1.00-1.05, p=0.019), FIGO stage 
(HR=1.97, 95%CI 1.09-3.57, p=0.025), Ki67 (HR=3.37, 95%CI 1.50-7.57, p=0.003) and CD8 
cancer epithelium (HR=0.86, 95%CI 0.74-0.99, p=0.038) as independent prognostic factors. 
The corresponding analysis with the whole core data revealed age (HR=1.03, 95%CI 1.01-1.05, 
p=0.015), FIGO stage (HR=1.99, 95%CI 1.10-3.62, p=0.024) and Ki67 (HR=3.53, 95%CI 
1.57-7.93, p=0.002) as independent prognostic factors, whereas CD8 whole core only remained 
as correcting factor for OS (HR=0.87, 95%CI 0.75-1.01, p=0.067). In both analyses, residual 
tumor remained as correcting factor, but was not significant (HR=1.65, 95%CI 0.94-2.88, 
p=0.079 and HR=1.69, 95%CI 0.97-2.97, p=0.066 for CD8 cancer epithelium and CD8 whole 
core, respectively). 
For PFS no significant influence of CD8 was observed in analyses omitting CD68 and 
CD45, neither for CD8 cancer epithelium nor for CD8 whole core data. As in PFS analysis 
including all assessed markers, FIGO stage (HR=2.11, 95%CI 1.38-3.22, p=0.001) and residual 
tumor (HR=1.68, 95%CI 1.10-2.56, p=0.017) were shown to be independent prognostic factors.  
 
The results of the separate analyses for CD68 omitting the markers CD8 and CD45 and 
for CD45 omitting the markers CD8 and CD68, respectively, were the same as the 
corresponding results in the analyses including all three leukocyte markers: CD68 did not have 
any impact on survival, neither on OS nor on PFS (data not shown); CD45 was significantly 
associated with improved OS (HR=0.83, 95%CI 0.70-0.98, p=0.031) and PFS (HR=0.86, 
95%CI 0.77-0.97, p=0.012); FIGO stage and Ki67 were independent factors for OS, while 
FIGO stage and residual tumor were associated with PFS. 
 
Interestingly, residual tumor was the only factor significant in univariate OS analysis 
(p=0.018), but loosing significance in multivariable OS analysis (p=0.157). Therefore and 
because the tumor mass which is targeted by anti-tumoral infiltrating leukocytes is removed in 
the cytoreductive surgery, it was assumed that the prognostic impact of tumor infiltrating 
immune cells might be weaker in optimally debulked patients (n=131) compared to patients 
with residual tumor (n=59). Indeed, separate analysis of the influence of CD8+ cell density 
(low versus high, cut-off value at the median) according to the debulking status revealed a 
     3 Results 
59 
 
significantly improved OS associated with high level of CD8+ cell infiltration compared to 
patients with low CD8+ cell infiltration in the group of patients with residual tumor mass (log-
rank test, p=0.001). In contrast, no OS difference according to the CD8+ cell density was 
observed in the group of optimally debulked patients (log-rank test, p=0.387). However, an 
interaction test for CD8+ cell density and residual tumor did not reach significance (p=0.102). 
The analogous analysis of the prognostic impact of CD45 (low versus high, cut-off value 
at the median) also showed a stronger positive effect of CD45+ cells on OS time in patients 
with residual tumor compared to patients without residual tumor. The Kaplan-Meier survival 
estimates in Figure 18A show the trend of survival advantage associated with high CD45+ cell 
tumor infiltration compared to low CD45+ cell infiltration in the group of non-optimally 
debulked patients, which did, however, not reach significance (log-rank test, p=0.103). In 
contrast, in women without residual tumor CD45+ cell infiltration did not influence OS (log-
rank test, p=0.215, Figure 18B). A test of interaction for CD45+ cell density and residual tumor 
showed significance (p=0.006). 
 
 
Figure 18. Kaplan-Meier curves showing the association between CD45 (low versus high, cut-off value at median) and 
patient overall survival. A Patients with residual tumor; log-rank test, p = 0.103; B optimally debulked patients; log-rank 
test, p = 0.215. 
 
Similarly, the prognostic value of residual tumor was separately assessed according to the 
tumor infiltration of CD8+ and CD45+ cells (low versus high, cut-off value at the respective 
median). The Kaplan-Meier survival estimates in Figure 19 show that the presence or absence 
of residual tumor after the cytoreductive surgery did not significantly influence OS in patients 
3 Results 
60 
 
with high CD8+ cell infiltration (log-rank test, p=0.574, figure 19A), whereas in patients with 
low CD8+ cell infiltration optimal debulking was associated with improved OS (log-rank test, 
p=0.001, Figure 19B). 
The analogous analysis of the prognostic impact of the debulking status according to the 
infiltration of CD45+ cells showed similar results: a trend of improved OS for optimally 
debulked patients compared to non-optimally debulked patients in the group of patients with 
low CD45+ cell infiltration (log-rank test, p=0.071). In contrast, no difference in OS time 
according to the debulking status was observed in the group of patients with high CD45+ cell 
infiltration (log-rank test, p=0.294). 
 
 
Figure 19. Kaplan-Meier curves showing the association between the debulking status and patient overall survival.  
A Patients with high infiltration of CD8+ cells (cut-off value at median); log-rank test, p = 0.574; B patients with low 
infiltration of CD8+ cells; log-rank test, p = 0.001. 
 
The presence of immune cell aggregates (regardless of the number and size) was not 
significantly associated with OS in univariate or multivariable analyses (data not shown). A 
trend of improved PFS was found for patients with immune cell aggregates in univariate 
analysis (HR=1.69, 95%CI 0.86-3.36, p=0.130), while this factor was not of independent 
prognostic value in multivariable PFS analysis (data not shown). 
 
RT-qPCR CD8 relative expression values were not associated with PFS or OS, neither in 
univariate nor in multivariable analyses (data not shown). 
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4 Discussion 
4.1 Blood cell gene signatures 
So far, no satisfying marker for early detection of EOC or prognosis in EOC patients has 
been established for routine use. In the search for a sophisticated diagnostic and prognostic 
peripheral blood biomarker or biomarker panel our working group has described two gene sets 
in a “high density” leukocyte fraction which is isolated from whole blood using a density 
gradient: one set for early detection comprising 13 gene expressions and six plasma protein 
abundances and another panel for prognosis comprising seven genes. For routine use the 
protocol to isolate the fraction, which is used for the determination of the gene signatures, from 
whole blood requires simplification. This study was aimed to find blood cell fractions 
appropriate to substitute the “high density” blood leukocyte fraction. The gene expression 
values of the genes comprised in these two panels were analyzed in seven different blood cell 
fractions from four EOC patients, six patients with other predominantly malignant diseases 
except ovarian cancer and 13 controls in order to identify the best suitable cell fraction(s). The 
blood cell fraction(s) of choice has(ve) to permit the discrimination of EOC patients and 
controls with the diagnostic panel and of EOC patients with a favorable outcome and patients 
with reduced survival time with the prognostic panel. These respective cell types could 
subsequently be targeted by immune magnetic separation methods to facilitate the protocol of 
the determination of the blood cell gene signatures. 
 
4.1.1 Diagnostic panel 
A single fraction obviously suitable for the evaluation of the diagnostic signature could 
not be identified. ANOVA and Bonferroni analyses revealed that the genes NEAT, AP2A1 and 
PAPOLG and the fractions CD19, CD3 (B and T cells, respectively) and CD44 (a mixture of 
tissue cells, erythrocytes and leukocytes) showed the most significant patient group specific 
expression patterns. Significantly different gene expression patterns were found between the 
two patient groups with malignances, EOC and other predominantly malignant diseases, 
including Krukenberg tumor, signet ring cell carcinoma, borderline tumor, lymphoma and 
teratoma, compared to the control group, comprising healthy individuals as well as patients 
with benign gynecological diseases such as hypermenorrhea, myoma, fibroma and CIN I/II. 
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Analysis of the relative risk of EOC, resulting from the combination of the 13 gene 
expression values determined in the “high density” leukocyte fraction, showed significantly 
higher values for the EOC patients and patients with other predominantly malignant diseases 
compared to the control group. The data generated in this work confirm sensitivity of the 
described panel determined in the “high density” blood leukocyte fraction to detect malignancy. 
However, the panel was not found to be EOC specific in this cohort. Only a trend of higher 
relative risk values for EOC patients compared to patients with other malignancies was found. 
This could be a result of a lack of specificity, the small patient number or the fact that analysis 
of the six plasma proteins, which are part of the complete diagnostic panel and which, 
presumably, contribute to EOC specificity, was not included in this study. A possible failure of 
the diagnostic gene panel to discriminate between the EOC patients and the patients with other 
malignancies of this study cohort could be due to the fact that women of the latter patient group 
predominantly suffered from malignant tumors in the peritoneal cavity. These peritoneal 
tumors might provoke similar host immune responses as EOC and thus similar blood leukocyte 
gene expressions. Concerning specificity, comparing EOC patients and controls, one outlier of 
the control group, a HPV-HR negative CIN II patient, with a relative risk value of about the 
order of the mean of EOC patients was apparent. Either this can be a result of low statistical 
specificity of the panel or the patient suffers from a malignant disease which has not been 
diagnosed yet. The relative risk values of EOC for the three HPV-HR positive patients were 
equal or below the 75th percentile of the control group indicating that a positive HPV-HR status 
in CIN patients does not result in higher relative risk values. 
Solely the relative risk values computed with the gene expression values in the HD 
fraction were significantly higher for patients with malignant diseases (EOC or other 
malignancies) compared to the control group. In contrast, the relative risk values computed 
with expression values in the other fractions did not permit discrimination between the patient 
groups. This observation was expected since the panel was developed with expression data in 
the HD fraction. When analyzing the genes separately, other fractions such as the fractions of 
enriched CD19+ and CD3+ cells were found to exhibit numerous significant gene expression 
differences between patient groups, while the HD fraction was among the fractions with fewer 
patient group specific gene expression values. This indicates that the analysis of a blood cell 
fraction with few significant up- or down-regulations in the single genes can permit better 
discrimination between patient groups than a fraction with more up- or down-regulations, 
providing that the genes of the panel in total are expressed differentially in the aforesaid 
fraction. 
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The non-uniform expression patterns of the genes of the diagnostic panel in the different 
blood cell fractions indicate that the panel measures gene expressions of several different cell 
types. Thus, the heterogeneity of the HD fraction could be suitable for the determination of this 
gene signature. Nevertheless, the fractions with most and/or highest gene expression 
differences between patient groups and also fraction CD25 that showed patient group 
dependent clustering in PCA should be considered for further analyses. The model for the 
determination of the relative risk of EOC with loadings of the genes developed with gene 
expression data in the HD fraction could only be used for expression data in another blood cell 
fraction if this distinct fraction was characterized by a similar cell composition as the HD 
fraction. Blood cell fractions isolated from whole blood might contain cell types which only 
marginally overlap with the cells in the HD fraction or which are not even present in the HD 
fraction. Thus, promising blood cell fractions might require a remodeling of the loadings of the 
13 genes in the discriminative model to achieve required sensitivity and specificity. But such an 
approach is time- and cost-consuming since a large independent sample cohort would be 
necessary. 
 
4.1.2 Prognostic panel 
In contrast to the diagnostic panel, the genes of the prognostic panel showed much more 
homogeneous expression patterns with peaks in the fractions of enriched CD25+ and CD14+ 
cells. The results of this study indicate that among the assessed blood cell fractions the genes of 
the prognostic panel are mainly expressed by CD14+ monocytes and monocyte derived cells 
(e.g. activated, thus CD25+) and/or other CD25+ activated immune cells. Interestingly, the two 
genes from the diagnostic panel NOXA1 and CCR2 showed similar expression patterns 
indicating similar cell types to be involved. Published microarray data, which have shown that 
CD25 is also expressed in monocytes, albeit in lower levels than in lymphocytes (Abbas et al., 
2005), suggest that cells captured by antibodies against CD14 and CD25 might partially 
overlap. A further indication for CD25 expression in monocyte derived cells provide an IHC 
study describing CD25+ macrophages in severe acute respiratory syndrome (SARS) patients 
(He et al., 2003) and microarray data showing up-regulation of CD25 in M1 polarized 
macrophages compared to monocytes and to M2 polarized macrophages (Martinez et al., 2006; 
Solinas et al., 2010). In light of these data, further analyses should be addressed to characterize 
the composition of the fractions CD14 and CD25. 
The study was not designed to analyze gene expression differences between EOC 
patients according to survival, since a much larger patient cohort would be necessary to analyze 
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differences between EOC patients regarding survival. Furthermore, at the time of sample 
collection and analysis follow-up time was too short to assess the clinical outcome. However, 
the fractions of CD14+ and CD25+ enriched cells seem must promising to be suitable for the 
determination of the prognostic gene panel. Nevertheless, to evaluate if a certain cell fraction is 
appropriate to discriminate between EOC patients according to the outcome, blood of a large 
EOC patient cohort has to be collected and analyzed.  
 
4.1.3 Principal Component Analysis 
Principal Component Analysis, a statistical method to reduce the complexity of 
multivariable data sets and to assess similarities of parameters, showed the strongest 
discrimination among all analyzed blood cell fractions between the fraction CD25 of EOC 
patients, on the one hand, and the fraction CD25 of patients with other predominantly 
malignant diseases and the controls, on the other hand. As expected, the HD fractions which 
have been reported to contain mainly granulocytes and lymphocytes (Brandt and Griwatz, 
1996) clustered together with the fractions of enriched CD15+ cells, the fractions of 
predominantly granulocytes and monocytes. Another cluster comprising the fractions CD3 and 
CD19 reflects the relation of T and B lymphocytes. The cell fractions enriched with an 
antibody against CD14, a monocyte marker, and the cell fractions enriched with an antibody 
against CD25, an activation marker expressed in various cell types, predominantly in 
lymphocytes, also clustered together. The clustering of the fractions CD14 and CD25 
represents the similarly high expression values of most genes of the prognostic panel and two 
genes of the diagnostic panel in these two fractions. As mentioned above, the CD14+ and 
CD25+ cells might (partially) overlap which could be the reason for the similar expression 
levels of some genes in the two fractions. As expected, the fractions of CD44+ enriched cells 
were localized in a central position of the biplot which reflects the composition of this fraction 
including tissue cells, erythrocytes and leukocytes.  
 
4.1.4 Limitations and outlook 
Regarding the comparison of the gene expression levels in the different blood cell 
fractions, one has to consider that the expression levels in a certain fraction do not give insight 
into the relative differences between patient groups or between EOC patients with different 
clinical outcome. High gene expression values in a certain fraction show that the respective 
genes are expressed in (some of) the cell types in the fraction which could – but need not – 
signify the suitability of the respective fraction for the evaluation of the gene signature. It is 
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also possible that in cell fractions, where a gene is generally expressed on a low level, the 
expression level is altered due to a malignant disease causing significant gene expression 
differences. Generally low expression levels, however significant expression differences 
between patient groups in several genes of the diagnostic panel, were for instance observed in 
the lymphocyte fractions CD19 and CD3. Therefore, subsequent studies assessing gene 
expression patterns in promising blood cell fractions require larger patient numbers in the 
groups to be compared. 
 
The composition of promising fractions could be further analyzed using fluorescence 
associated cell sorting (FACS) or other marker specific cell sorting methods. The assessment of 
the expression of markers which have been used to enrich the distinct fractions could reveal 
eventual overlaps. Moreover, these techniques could be used to obtain higher purity of cells 
which could improve the gene signatures. However, as the final aim in the search for 
biomarkers for early detection of EOC and for prognosis in patients with diagnosed EOC is the 
screening of numerous patients, too advanced and time-consuming protocols requiring special 
technical equipment and/or know-how have to be avoided for routine applications. In the case 
of both gene panels the method of choice for cell separation should consist of a possibly short 
and simple protocol, such as the filtering system used in this study or an immune magnetic 
separation method. 
 
The main complicacy in the gene expression analysis was that some samples had very 
low RNA concentrations and gene expression values in some of these samples were below the 
detection level and were thus imputed for the subsequent analyses. 
It was impossible to collect more blood samples of EOC patients in the course of the 
diploma thesis since EOC is a rare disease. The collection of samples of ten EOC patients was 
initially planned. In some cases the final diagnosis was only obtained months after taking of the 
blood samples which complicated subsequent analyses. Among the ten patients with suspected 
ovarian cancer only four cases were confirmed, while in six patients other predominantly 
malignant diseases were diagnosed. This lower number of EOC cases diminished the statistical 
power. However, the unexpected collection of samples of patients with other malignancies 
allowed the assessment of the diagnostic gene panel regarding its applicability for the 
discrimination between EOC and other malignancies. 
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4.2 Tumor microenvironment 
In ovarian cancer tumor characteristics such as proliferation and tumor infiltrating 
immune cells have been addressed in several studies in the last years. However, very little data 
about the interaction of the local immune system and ovarian cancer growth has been 
published. Therefore, in this study detailed analyses of the proliferation marker Ki67 as well as 
CD8+, CD68+ and CD45+ cells in the tumor microenvironment in ovarian cancer patients was 
performed and the impact on the clinical outcome was studied. The study cohort comprised 
more than 200 EOC patients for whom a broad and well-described tumor bank and database of 
the clinicopathological data had been established. A very low percentage of Ki67+ tumor cells 
was associated with worse OS. Moreover, patients with tumors characterized by high CD45+ 
cell infiltration were identified to have improved OS and PFS. 
 
4.2.1 Study population 
In the OVCAD consortium multiple centers are involved which permitted the collection 
of this large number of EOC tissue samples, predominantly with advanced stage and mainly of 
serous histology. In a single center this could not have been accomplished for a rare disease 
such as EOC. A big and relatively homogeneous study population is essential for a meaningful 
statistical analysis of interactions of biological markers and especially for survival analyses.  
 
4.2.2 Immunohistochemical staining 
The median values of leukocyte cell density and the Ki67 labeling index in this study are 
similar to data from other studies (Aune et al., 2011; Garcia-Velasco et al., 2008; Hamanishi et 
al., 2007; Sato et al., 2005). Clusters of immune cells with high numbers of CD8+, CD68+ 
and/or CD45+ cells were observed in about 10% of the tumor samples. Interestingly, only few 
studies have described similar aggregates of immune cells – mainly lymphocytes – in human 
cancer entities: in breast cancer (Liu et al., 2011), non-small-cell lung cancer (Dieu-Nosjean et 
al., 2008), bladder cancer (Ayari et al., 2009) and ovarian cancer (Anderson et al., 2009; Sato et 
al., 2005). 
Correlation and survival analyses revealed almost identical results for CD8 whole core 
(HR=0.88, 95%CI 0.76-1.02, p=0.081) and CD8 cancer epithelium (HR=0.88, 95%CI 0.77-
1.01, p=0.077), although it is generally recommended to assess only intraepithelial leukocytes 
in the tumor microenvironment (Hamanishi et al., 2007; Sato et al., 2005). On the one hand, 
this can be explained by the fact that the analyzed TMA cores comprised mainly tumor cells 
and putative “stromal contamination” attenuating the statistical significance seemed to be 
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neglectable. On the other hand, cancer epithelium and stroma could yield similar infiltration 
values. Considering the very limited – if any – improvement of data and the time-consuming 
process of the manual selection of cancer epithelium, the other studied leukocytes were 
quantified solely in the whole TMA core including cancer epithelium as well as stromal areas. 
However, it is possible that a separate analysis of leukocyte infiltration in the cancer epithelium 
and in the tumor stroma would slightly change results. For CD8, analyses of positive cells 
assessed in the cancer epithelium showed slightly smaller p values than analyses of positive 
cells assessed in the whole core. Thus, separate quantification of intraepithelial cells could have 
an impact on the prognostic value of CD45 since p values were just below the significance 
level. However, for CD68 only intraepithelial cells would presumably not change correlation 
and survival analyses considerably since this marker was far from significance in all survival 
analyses. Therefore, in studies including numerous markers and/or a large sample size, analysis 
can be performed with the whole TMA core and – if promising – be repeated with separate 
quantification of intraepithelial and stromal cells. 
 
As expected, cells positive for the panleukocyte cell marker CD45 were more frequent 
than cells positive for the more specific cytotoxic T cell and macrophage markers CD8 and 
CD68. Similarly, total leukocyte numbers correlated with both, cytotoxic T cell and 
macrophage cell numbers (R=0.71 and R=0.58, respectively), while the number of cytotoxic T 
cells and macrophages did not correlate with each other (R=0.35). The found association 
between the presence of immune cell aggregates and the densities of CD8+, CD68+ and 
CD45+ was also expected. 
 
Inflammation, one of the hallmarks of cancer, contributes to tumorigenesis and tumor 
progression by inducing cell proliferation, resistance to cell death and angiogenesis via the 
release of bioactive molecules including growth, survival and pro-angiogenic factors to the 
tumor microenvironment (Hanahan and Weinberg, 2011). Therefore, the association between 
tumor infiltrating immune cells and tumor cell proliferation was assessed. In this study cell 
proliferation, measured by Ki67 expression, did not correlate with tumor infiltrating CD8+, 
CD68+ or CD45+ cells or the presence of immune cell aggregates. This finding demonstrates 
that tumor cell proliferation is not essential for the infiltration of leukocytes and that infiltrating 
leukocytes do not contribute to tumor cell proliferation in human ovarian cancer tissue, 
respectively. 
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4.2.3 Immunofluorescent staining 
Macrophages (CD68+) were detected in all tumor samples with percentages of total cells 
ranging from very low (1%) up to approximately 20%. Most macrophages in the tumor tissue  
– between 50% and almost 100% – expressed the alternatively activated macrophage marker 
MSR1. The bimodal distribution of the percentages of macrophages of total cells and the 
percentages of alternatively activated macrophages of total macrophages in this data set could 
be a result of the sample selection of the study only including patients with very high and very 
low PC1 and PC2 values.  
Concerning the analysis of the polarization of TAMs towards M1 or M2, I was aware of 
the problem of false positive signals with only one marker. However, no description of a M1 
marker tested for EOC tissue was found in literature. Thus, M1 markers described for other 
tissues (CD80, iNOS and HLA-DR) were tested (Escorcio-Correia and Hagemann, 2010; Ma et 
al., 2010). Nevertheless, no satisfying staining protocol with a specific marker for classically 
activated macrophages could be established: Two of the three tested corresponding antibodies 
(CD80, iNOS) showed also reactivity on some EOC tissues. The third tested antibody  
(HLA-DR) was negative for EOC, but stained some MSR1+CD68+ double positive cells. As 
these cells were considered as M2 macrophages, HLA-DR was not appropriate to use in 
combination with MSR1. Due to these practical shortcomings analysis of classically activated 
macrophages was omitted. Alternatively, CD68+ cells were considered as total macrophages 
and MSR1+CD68+ cells were considered as alternatively activated macrophages. 
 
4.2.4 Correlation of TAMs and the prognostic blood cell signature 
To assess a possible interaction between blood cells involved in the prognostic gene 
panel and tumor infiltrating total (CD68+) and alternatively activated (MSR1+CD68+) 
macrophages, the small cohort of 19 patients was especially selected according to results from 
the prognostic gene signature. Patients with very high and very low PC1 and PC2 values 
indicating risk to die (OS) and risk of death within two years after EOC diagnosis, respectively, 
were included in the study. Although an interaction between blood leukocytes and leukocytes 
in the tumor microenvironment was presumed, the high statistical significance of the revealed 
moderate correlation between PC1 and the percentage of alternatively activated macrophages of 
total macrophages (R=0.71, p=0.006) was not expected in this small cohort. Interestingly, no 
association of the total macrophage data and the alternatively activated macrophage data with 
PC2 was found. As PC1 and PC2 are independently prognostic for two separate outcome 
parameters, it can be assumed that they represent two distinct biological features such as cell 
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type or activation state. Thus, the correlation of alternatively activated macrophages with PC1 
and the lack of an association with PC2 indicate that PC1 is related to alternatively activated 
macrophages at the tumor site, whereas PC2 represents a distinct immunological characteristic. 
To my knowledge, this is the first study revealing an association between a prognostic 
blood cell signature and tumor infiltrating leukocytes. However, a study on mice bearing 
mammary tumors has reported a similar phenotype for blood monocytes and peritoneal 
macrophages. Both are neither completely inflammatory nor suppressive and are less 
differentiated than monocytes and macrophages from normal mice (Caso et al., 2010). 
These data indicate a direct or indirect interaction between blood cells involved in the 
prognostic gene panel and alternatively activated macrophages located in the tumor tissue. It is 
possible that the prognostic gene panel reflects the polarization of blood monocytes that is 
related to the polarization of macrophages in the tumor tissue, which was assessed by IF. It 
remains to be elucidated, whether the blood cell gene signature derives from the same cell line 
as the M2 macrophages or whether different cell types (blood versus tissue) are measured but 
responding to the same biological event – ovarian cancer. Moreover, it is unclear if these cells 
are able to migrate between the tumor tissue and the peripheral blood. To gain more insight into 
the interaction between blood and tumor tissue immune cells, detailed FACS analyses are 
planned. Blood samples and single cell suspensions of enzyme-digested tumor tissues will be 
characterized for their leukocyte composition. Markers specific for total leukocytes, subtypes of 
T and B lymphocytes, NK cells, granulocytes, MDSCs, monocytes and macrophages as well as 
activation and differentiation markers will be used to extend the analysis performed in the 
current study on additional cell types. The ratios of the different cell types will be compared 
between peripheral blood and tumor tissue. 
 
No further correlation with other biological or clinical factors or survival analysis was 
performed, since this subproject was designed to correlate the number and polarization of 
TAMs with the prognostic gene panel in a relatively small patient cohort, but not to provide 
statistical power for survival analyses. However, the revealed correlation between M2 
macrophages and PC1 (associated with decreased OS) indicates a survival disadvantage for 
patients with high percentages of M2 macrophages. Consistently, high numbers of M2 
macrophages have been associated with worse clinical outcome in several cancer entities 
(Escorcio-Correia and Hagemann, 2010). Thus, the positive correlation of PC1 and M2 
macrophages is in accordance with the reported negative effect of M2 macrophages in the 
tumor microenvironment on tumor regression and survival. For ovarian cancer functional and 
differentiation studies about macrophages have been published (Kawamura et al., 2009; 
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Takaishi et al., 2010; Wang et al., 2010), but little is known about the prognostic impact of M2 
macrophages for ovarian cancer patients. To approach this question, subsequent analyses 
including a larger number of tumor tissue samples and sophisticated marker panels for M1 and 
M2 macrophages would be necessary. 
 
4.2.5 RT-qPCR CD8 relative expression values  
Currently, many studies on prognostic markers are carried out by evaluating mRNA 
expression. Recent publications, however, have shown little or no correlation between protein 
and mRNA expression for some genes (Rabiau et al., 2011; Szanto et al., 2011). In this study, 
the CD8 gene expression values obtained from RT-qPCR did not correlate with the CD8 data 
generated by IHC. In addition, the prognostic impact of CD8+ cells in the cancer epithelium 
could not be proven by CD8 gene expression. These differences may be attributed to the fact 
that the RT-qPCR analysis is based on RNA/cDNA obtained from heterogeneous tumor tissue 
samples consisting of tumor cells, but also of stromal fibroblasts and blood vessels, whereas for 
the IHC staining tissue areas with possibly high ratios of tumor cells were selected. Similarly, 
CD8 assessed in the whole core only showed a trend of improved OS, while the prognostic 
impact of CD8 data assessed in the cancer epithelium was of significance. These results 
indicate that when analyzing infiltrating immune cells, gene transcription measurements may 
not be suitable, at least if tumor tissues are not micro-dissected. RNA in situ assays which 
permit the assessment of RNA expression on FFPE tissue slides (e.g. QuantiGene® ViewRNA 
ISH Tissue Assay, Affymetrix, USA) could be a preferable alternative method to RT-qPCR 
since cancer epithelium and stromal areas can be separately analyzed with this technique. 
However, two distinct expression levels transcription/RNA stability and translation/protein 
stability are measured by RT-PCR or RNA in situ assays, on the one hand, and IHC, on the 
other hand, which per se can lead to uncorrelated results. 
 
4.2.6 Correlation with clinicopathological factors 
No associations with the clinicopathological parameters were found for the assessed 
leukocytes, leukocyte aggregates, Ki67 and CD8 relative expression values, which is in 
accordance with other studies also reporting no association of TILs and Ki67 with 
clinicopathological parameters (Adams et al., 2009; Sengupta et al., 2000). However, other 
studies reported an association of high Ki67 proliferation index with advanced stage and high 
grade in ovarian cancer (Aune et al., 2011; Kulkarni et al., 2007). The confirmed association 
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between FIGO stage and residual tumor (p=0.009) is in line with previous studies (Polterauer et 
al., 2012). 
 
4.2.7 Survival analyses 
CD45+ cell infiltration and Ki67 labeling index were found to be independent prognostic 
factors in multivariable OS analysis. Besides these two biological marker, the well-known 
clinicopathological prognostic factors high age and advanced FIGO stage were associated with 
shorter OS, which is in accordance with previous studies (Holschneider and Berek, 2000; 
Leffers et al., 2009). In PFS analysis, the factors CD45+ cell infiltration, FIGO stage and 
residual tumor after cytoreductive surgery were found to be of independent prognostic value. 
The predictive power of FIGO stage and residual tumor for survival is in accordance with 
literature also reporting these two clinicopathological characteristics to be the most significant 
prognostic factors (Holschneider and Berek, 2000; Leffers et al., 2009). 
 
Dichotomization of Ki67 at 5% according to the shape of its non-linear association with 
survival showed a significantly worse survival for a small population of ovarian cancer patients 
with no or very few Ki67+ tumor cells in their primary tumors compared to patients with ≥5% 
Ki67+ tumor cells (univariate analysis: p=0.004; log-rank test: p=0.002). In contrast, no 
survival advantage was observed when using the median as cut-off value or the continuous 
values. In multivariable analysis, patients with Ki67- tumors (<5% Ki67+ tumor cells) were 
found to have a more than three times higher risk of death compared to patients with Ki67+ 
tumors. An association of the proliferative status of ovarian cancer with survival has been 
reported recently using other proliferation markers such as p21-activated kinase 4 (PAK4) (Siu 
et al., 2010) or cell cycle-related kinase (CCRK) (Wu et al., 2009). However, there are few 
reports about the prognostic value of the cell proliferation marker Ki67 for ovarian cancer. 
Furthermore, patients with Ki67- tumors were found to be proportionally  
over-represented in the group of patients who had refractory disease (progression of disease 
while receiving first line platinum-based therapy or within four weeks after the last 
chemotherapy cycle) compared to Ki67- tumors in the remaining group of patients. Similarly, a 
positive correlation between clinical complete response to first-line chemotherapy and high 
Ki67 labeling index has been reported (Aune et al., 2011; Garcia-Velasco et al., 2008). All 
patients included in this study received a platinum-based chemotherapy, in which the platinum 
complexes cause crosslinking of DNA and trigger apoptosis of the tumor cells. Platinum, like 
other cytotoxic drugs, is believed to gain its specificity by preferentially killing proliferating 
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cells. Thus, the dramatically worse clinical outcome of patients with no or very few Ki67+ 
tumor cells could indicate that these tumor cells may have lower or no response to the 
platinum-based chemotherapeutic drug. On the other hand, rapidly proliferating tumors are 
expected to cause poor PFS since these tumors may grow faster to visible recurrent disease. 
The correlation between Ki67 labeling index and PFS could not be evaluated for the patients 
with refractory disease who comprised five out of the eleven patients with Ki67- tumors. 
Hence, the reported correlation between Ki67 labeling index and PFS correlation could only be 
examined for about half of the patients with Ki67- tumors (and the majority of patients with 
Ki67+ tumors) and was not confirmed in the current study. 
Ovarian cancer patients have a poor prognosis with a less than 40% five year survival for 
advanced stages (Holschneider and Berek, 2000). About 25% of the patients do not respond to 
chemotherapy. It is therefore rational to identify the non-responders already at the time of 
surgery, in order to avoid a harmful but ineffective chemotherapy and to eventually apply 
alternative therapies. The prevalence of Ki67- tumors is about 5% in the current study including 
more than 200 EOC patients. If women with Ki67- tumors could be identified at the time of 
surgery, they could be selected for treatment with alternative drugs, such as angiogenesis 
inhibitors that reduce tumor growth by inhibiting blood vessel formation rather than targeting 
rapidly proliferating cells. Studies comprising larger cohorts of patients with Ki67- tumors are 
needed to further elucidate the clinical relevance of the tumor proliferation marker Ki67 with 
special focus on response to chemotherapy. Furthermore, the assessment of the Ki67 is well 
suitable for clinical applications, since standardized, relatively short protocols for Ki67 
immunohistochemical staining are available. However, to further elucidate the cause of the 
worse outcome of patients with Ki67- tumors, the proliferation status of these tumors should be 
assessed with other proliferation markers specific for proteins which might complement Ki67. 
 
The important role of TILs in human ovarian cancer has recently been investigated in 
several studies (Curiel et al., 2004; Sato et al., 2005; Zhang et al., 2003). In contrast, there are 
only few descriptions of CD68+ and CD45+ cells in literature. In the current study high CD45+ 
cell infiltration was identified as an independent prognostic factor for prolonged survival. The 
HR per each cell number doubling was reduced by approximately 15% for OS and PFS. This is 
equal to a reduction of risk to die and risk of disease recurrence of approximately 60% for 
patients with CD45+ cell infiltrations equivalent to the 75th percentile compared to patients with 
CD45+ cell densities equivalent to the 25th percentile infiltration. 
Interestingly, CD8+ cytotoxic T cells did not have any prognostic impact in multivariable 
survival analyses including the clinicopathological factors as well as the other assessed 
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biological markers. This finding is in contrast to most literature describing CD8+ TILs as an 
independent prognostic factor in ovarian cancer patients (Leffers et al., 2009; Milne et al., 
2009; Sato et al., 2005; Zhang et al., 2003). In the current study high CD8+ T cell infiltration 
only showed a trend of improved OS in univariate analysis (CD8 cancer epithelium: HR=0.88, 
95% CI 0.77-1.01, p=0.077 and CD8 whole core: HR=0.88, 95%CI 0.76-1.02, p=0.081). This 
apparent discrepancy might be a result of the fact that these earlier studies showing CD8+ cells 
as an independent prognostic factor did not regard the macrophage marker CD68 and the 
panleukocyte marker CD45 in multivariable survival analyses. Considering these methodical 
differences and the positive prognostic trend of cytotoxic T cells in univariate analysis, 
multivariable analysis was repeated omitting the leukocyte markers CD45 and CD68. 
Interestingly, in this analysis intraepithelial CD8+ TILs were an independent prognostic factor 
for OS. This observation indicates inferiority of the prognostic value of CD8+ cytotoxic T cells 
to that of CD45+ total leukocytes causing the exclusion of CD8+ cell infiltration in the 
multivariable model comprising CD45. For CD68+ macrophages no impact on patients’ 
survival was found in any of the analyses. This could be due to the expression of CD68 in 
macrophages with pro- as well as anti-tumoral activities. The much stronger prognostic effect 
of CD45 compared to CD8 and CD68 suggests that the amount of the total immune cell 
infiltration is an informative measure of anti-tumoral activity. Due to its panleukocytic 
reactivity, CD45 indicates most globally, but least specifically an ongoing immune response 
without revealing the single cell types and their functions. Although the number of CD45+ cells 
does not provide information about the ratios of the distinct immune cell types with pro- and 
anti-tumoral functions included in the CD45+ cells, the association of high CD45+ cell 
infiltration with improved survival, suggest that leukocytes accomplishing tumor regression 
predominate over immunosuppressive leukocytes favoring tumor progression.  
 
In a successful cytoreductive surgery the major target of anti-tumoral infiltrating immune 
cells – the tumor mass – is removed as well as the associated infiltrating immune cells. 
Presumably, different immune cells are involved in inhibiting metastasis formation in the case 
of optimally debulked patients than the tumor infiltrating immune cells that accomplish the 
control of tumor outgrowth in patients who suffer from residual tumor. Therefore, it was 
assumed that in the latter patient group the effect of tumor infiltrating immune cells is more 
important. Moreover, the factor residual tumor was significant in univariate analysis, but was 
not significant in multivariable analysis. This led to an additional question regarding the 
influence of cytotoxic T cells and total leukocytes separately in patients with and without 
residual tumor. The interaction test and the separate analyses of these two groups of patients 
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indicated that the positive effect of cytotoxic T cells and total leukocytes on patients’ outcome 
was dependent on the debulking status: a stronger association of CD8+ and CD45+ cell 
infiltration with improved OS in the group of non-optimally debulked patients compared to the 
group of optimally debulked patients. The assessment of the prognostic value of the debulking 
status according to the infiltration of cytotoxic T cells and total leukocytes indicated a 
dependency of the prognostic impact of the factor residual tumor on the number of cytotoxic T 
cells and total leukocytes in the tumor mass. The data generated in this study suggest that 
patients with low CD8+ cell infiltration benefit more from an aggressive cytoreductive surgery 
than patients with high CD8+ cell tumor infiltration. An explanation for this finding could be 
that only in the latter patient group the cytotoxic activity of CD8+ T cells limits tumor 
progression of residual tumor mass, while patients with a low immune cell infiltration have 
fewer immunological armaments to combat tumor progression. The same trend was observed 
for CD45+ cells. 
These findings are in accordance with a recently published study also reporting a more 
likely benefit of surgical debulking for patients with aggressive tumor behavior with low CD8+ 
infiltration and high Ki67 expression (Adams et al., 2009). However, for the latter tumor type 
the finding was not confirmed in the current study. In accordance with Adams et al., a currently 
published meta-analysis has shown a varying prognostic impact of CD8 in ovarian cancer 
patients according to the debulking status. The study has also outlined higher HRs for CD8 in 
studies comprising optimally and non-optimally debulked patients compared to studies 
including only optimally debulked patients (Hwang et al., 2012). Together, these results 
suggest that in non-optimally debulked patients, where tumor infiltrating leukocytes coexist 
with the residual tumor cells, a higher infiltration presumably correlates with an improved 
survival due to the contribution of infiltrating leukocytes to tumor regression. In contrast, in 
optimally debulked patients the tumor and the infiltrating leukocytes are removed and 
leukocyte cell densities in the primary tumor tissue will have a weaker or no impact on 
patients’ survival. Moreover, CD8 seems a promising marker to predict extent of benefit from 
extensive surgery for the patients. Quantification of tumor infiltrating cytotoxic T cells could be 
performed in clinical routine to decide to which extent aggressive cytoreductive surgery should 
be conducted in patients in whom optimal debulking is difficult and risky to achieve  
However, the possible varying prognostic impact of CD8+ and CD45+ cells according to 
the debulking status and the apparent dependency of the positive effect of optimal debulking on 
OS according to the infiltration of CD8+ and CD45+ cells described here have to be validated 
in independent studies.  
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Concerning residual tumor, inconsistent cut-off values are in use. Several studies define 
the cut-off value for optimal debulking at 1 or 2 cm (Leffers et al., 2009; Shah et al., 2008; 
Stumpf et al., 2009), whereas others consider residual tumor as macroscopically visible tumor 
load as in this study (Clarke et al., 2009; Milne et al., 2009). The question of the influence of 
residual tumor on the outcome in ovarian cancer patients has recently been addressed in a study 
stating that for FIGO IV patients macroscopically complete resection was associated with 
improved survival compared to patients with macroscopically visible residual tumor (≥0.1 cm). 
Categorizing the latter subgroup into patients with minimal residual disease of 0.1 to 1 cm and 
patients with residual tumor larger than 1 cm, both groups showed similar results (Wimberger 
et al., 2010). Another study has reported survival advantages for patients without 
macroscopically visible residual tumor compared to those with minimal visible tumor load  
(≤1 cm) as well as for patients with minimal visible tumor mass (≤1 cm) compared to those 
with residual tumor exceeding 1 cm (Chang and Bristow, 2012). These different definitions of 
residual tumor have to be taken into account when comparing results. 
 
Clusters of immune cells with high numbers of CD8+, CD68+ and/or CD45+ cells 
indicate an active immune reaction and might be of prognostic value. No detailed analyses of 
the cellular composition and the relevance of these aggregates in the anti-tumoral response have 
been published so far. In this study a trend of improved PFS for the 10% of patients with 
leukocyte clusters was found suggesting that the presence of immune cell aggregates could be a 
prognostic factor in ovarian cancer patients. Presumably, a more detailed analysis including the 
cellular composition, the size and number of such immune cell clusters could increase the 
prognostic value of these immune cell clusters. 
 
The biological role of tumor infiltrating immune cells in ovarian cancer remains to be 
further elucidated regarding their pro- and anti-tumoral functions in the complex interplay with 
tumor cells and stroma cells. For more functional analyses differentiation and activation 
markers of immune cells should be additionally assessed. Information restricted to cell numbers 
do not allow interpretation of the actual effector functions or eventual immunosuppressive 
effects of regulative immune cells such as Tregs or M2 macrophages on anti-tumoral effector 
cells. Besides the local immune system in the tumor microenvironment, additional mechanisms 
involved in tumor progression and dissemination such as resistance to cell death, angiogenesis, 
metastasis or genome instability, which have been reviewed recently (Hanahan and Weinberg, 
2011), could be of prognostic value and should be addressed in pursuing studies.  
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4.2.8 Trouble shooting and limitations 
The immunohistochemical analysis revealed information about the prognostic relevance 
of biological markers such as tumor proliferation and leukocyte infiltration. Nevertheless, the 
analysis was limited by the use of TMAs comprising only two tissue cores per tumor sample 
that might not perfectly represent WTSs regarding inhomogeneously distributed tumor 
infiltrating immune cells. However, for a study comprising hundreds of tumor tissue samples, 
the use of TMAs provides numerous practical advantages: The TMA technology is relatively 
inexpensive, preserves patients’ material and allows rapid evaluation of different tissues under 
homogenous conditions. Moreover, if a biological factor of interest has a considerable impact, 
it should also manifest in TMA analyses. Weighing thoroughly the pros and cons of TMA and 
WTS, a larger sample size analyzed with TMA technology was preferred over a smaller sample 
size analyzed with WTSs. However, more reliable data could be obtained when using TMAs 
with three or even more tissue cores per tumor sample. 
Difficulties in the evaluation of the immunohistochemical staining were that some cores 
did not contain tumor cells (Figure 20A and B) or that they were lost during processing  
(Figure 20C).  
 
 
Figure 20. Non-evaluable immunohistochemically stained tissue microarray cores of epithelial ovarian cancer due to lack 
of tumor cells or high background in cancer epithelium and/or necrotic areas; A fat tissue; B tumor stroma tissue; C loss 
of tissue; D high CD68 background in tumor cells; E high CD8 background in tumor cells; F necrotic areas highly 
positive for CD68; optical magnification x200; images acquired with the TissueFAXS/HistoQuest system. 
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Another problem was high background staining: Various tumor samples showed 
background signals for some of the antibodies either due to expression of the respective antigen 
or due to unspecific binding of antibodies (Figure 20D and E). Necrotic areas within the tumor 
tissue also impeded meaningful quantification of marker positive cells since these areas were 
characterized by unspecific binding and/or high infiltration of immune cells, which were first 
too dense to be quantified and second might have biased the results. Especially for the 
quantification of CD68, necrotic areas were problematic (Figure 20F). Therefore,  
non-evaluable cores or parts of cores lacking cancer epithelium, high background or large 
necrotic areas were excluded from analysis. 
For the analysis of the immunofluorescent staining of WTSs the strong autofluorescence 
of erythrocytes (Figure 21A and B) was the major problem. As described above, it was 
impossible to meaningfully analyze necrotic tissue, possibly due to autofluorescence, 
unspecific binding of antibodies or high macrophage infiltration (Figure 21C and D). Due to 
difficulties in finding appropriate fields of view without false positive signals, only eight FOVS 
per WTS were analyzed. 
 
Figure 21. Non-evaluable fields of view of immunofluorescence double staining with antibodies against CD68 (red) and 
MSR1 (green) of epithelial ovarian cancer tissue; DAPI as nuclear counterstaining (light grey); A and B autofluorescence 
of erythrocytes; C and D non-evaluable necrotic areas; optical magnification x200; images acquired with the 
TissueFAXS/HistoQuest system. 
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Analyzing the AlexaFluor® 568 detected cells much more false positive signals were 
observed, whereas hardly any background/autofluorescence complicated the evaluation of 
AlexaFluor® 647 detected cells. Therefore, a strategy to circumvent the problem of false 
positive signals might be to use fluorophores emitting in the long-wavelength spectrum. 
However, the microscope which was used in this study did not provide the filters to use two 
fluorophores of this kind simultaneously. 
 
4.3 Conclusion 
The data obtained from the analysis of gene expression patterns in different blood cell 
fractions from 23 patients showed heterogeneous expression patterns for the genes comprised 
in the diagnostic panel. No single cell types obviously suitable for the determination of the 
diagnostic signature could be identified. However, the fractions of enriched CD3+, CD19+, 
CD44+ and CD25+ cells seem most promising for patient group specific differences and should 
be regarded for further analyses. The EOC sensitivity of the diagnostic gene panel determined 
in the “high density” fraction was confirmed in this study, but the signature was not found to be 
EOC specific. 
For the prognostic panel the gene expression patterns indicate that among the assessed 
blood cell fractions the genes of this panel are mainly expressed by monocyte derived cells and 
activated immune cells or from “activated monocytes”. 
 
The immunohistochemical analysis of more than 200 relatively homogeneous EOC 
samples revealed a dramatically worse clinical outcome for patients with Ki67- tumors, 
presumably due to poor response to the chemotherapy. Moreover, high CD45+ cell infiltrating 
of the tumor was associated with prolonged survival, thereby indicating a predominance of 
anti-tumoral activity over pro-tumoral functions in the total of immune reactions. Interestingly, 
cytotoxic T cells and total leukocytes were found to have a stronger positive effect on the 
clinical outcome in patients with residual tumor compared to optimally debulked patients. 
Similarly, the prolonged overall survival associated with optimal debulking was found to 
depend on the infiltration level of cytotoxic T cells and total leukocytes. Summarizing, Ki67 
and CD8 could be useful clinical tools for the choice of chemotherapy and as a predictive 
marker for patients’ benefit from an aggressive cytoreductive surgery, respectively. CD45 
could be used as a prognostic marker for overall and progression-free survival. 
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The analysis of the interaction of blood cell leukocytes represented by the two 
independent prognostic factors PC1 and PC2 derived from the prognostic gene panel and tumor 
infiltrating macrophages revealed a correlation between M2 macrophages and PC1. This is in 
accordance with the repeatedly reported positive correlation of M2 macrophages and tumor 
progression. The observed association indicates a direct or indirect interaction between blood 
cells involved in the prognostic gene panel and M2 macrophages.  
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ANOVA    analysis of variance 
CA     cancer antigen 
CCRK     cell cycle-related kinase 
CI     confidence interval 
CIN     cervical intraepithelial neoplasia 
CTC     circulating tumor cell 
CTLA-4    cytotoxic T lymphocyte antigen 4 
DAB     diamino-benzidine 
DC     dendritic cell 
EGF     epidermal growth factor 
EOC     epithelial ovarian cancer 
EOK     epitheliales Ovarialkarzinom 
FACS     fluorescence associated cell sorting 
FIGO     International Federation of Gynecology and Obstetrics 
FOV     field of view 
GM-CSF    granulocyte macrophage colony-stimulating factor 
HD     high density 
HE4     human epididymis protein 4 
HER-2/neu    human epidermal growth factor receptor 2 
HLA     human leukocyte antigen 
HPV-HR    human papilloma virus – high risk 
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HR     hazard ratio 
HRP     horseradish peroxidase 
IF     immunofluorescence 
IFN     interferon 
IGF-II     insulin-like growth factor II 
IHC     immunohistochemistry 
IL     interleukin 
iNOS     inducible nitric oxide synthase 
JAK     janus kinase 
LPS     lipopolysaccharide 
MDSC     myeloid derived suppressor cell 
MHC     major histocompatibility complex 
MIF     macrophage migration inhibitory factor 
MSR1     macrophage scavenger receptor 1 
NK     natural killer 
NO     nitric oxide  
OS     overall survival 
PAI     plasminogen activator inhibitor type 
PAK4     p21-activated kinase 4 
PBMC     peripheral blood mononuclear cell 
PC     Principal Component 
PCA     Principal Component Analysis 
PD-L1     programmed death-1 ligand 
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PFS     progression-free survival 
PGE2     prostaglandin E2 
RIN     RNA Integrity Number  
ROI     region of interest 
ROS     reactive oxygen species 
RT-qPCR    reverse transcriptase quantitative PCR 
SARS     severe acute respiratory syndrome 
SMRP     soluble mesothelin-related peptide 
STAT     signal transducer and activator of transcription 
TAM     tumor associated macrophage 
TGF     transforming growth factor 
Th     T helper 
TIL     tumor infiltrating lymphocyte 
TLR     toll-like receptor 
TMA     tissue microarray 
TNF     tumor necrosis factor 
Treg     regulatory T cell 
TSP     thrombospondin 
VEGF     vascular endothelial growth factor 
WTS     whole tissue section 
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6 Abstract 
Ovarian cancer is one of the most deadly malignancies in women. Due to a lack of 
symptoms and a routinely used screening marker most patients are diagnosed at advanced 
stages and have a five year survival rate below 40%. Thus, to improve overall survival, new 
diagnostic and prognostic markers are urgently needed. Our working group has developed two 
gene expression signatures in a blood leukocyte fraction which is isolated using a density 
gradient: one for early diagnosis of epithelial ovarian cancer (EOC) and another one for 
prognosis in EOC patients. Besides blood cell gene expressions, tumor proliferation markers 
and tumor infiltrating leukocytes are promising prognostic biological markers in EOC patients.  
In the course of this diploma thesis expression patterns of the genes comprised in the two 
recently described blood cell signatures were analyzed with reverse transcriptase quantitative 
PCR in different blood cell fractions. 23 patients including EOC patients, patients with other 
malignancies and controls with benign gynecological diseases were compared. The study aimed 
to find blood cell fraction(s) suitable for the determination of the gene signatures to facilitate 
the current density gradient protocol. The gene expression patterns of the diagnostic panel were 
heterogeneous suggesting various different cell types expressing these genes. The fractions of 
CD3+, CD19+, CD44+ and CD25+ enriched cells were the fractions with highest disease 
specific gene expression differences. Most genes of the prognostic gene panel showed highest 
expression values in the fractions of CD14+ and CD25+ enriched cells indicating these genes to 
be mainly expressed by monocyte derived cells and activated immune cells. 
Moreover, in more than 200 EOC patients proliferation activity, measured by Ki67 
expression, and tumor infiltrating CD8+, CD68+ and CD45+ cells were 
immunohistochemically analyzed and the prognostic values of these biological markers were 
assessed. A dramatically diminished overall survival for a small population of patients with no 
or very few Ki67+ tumor cells was revealed, presumably due to poor response to the 
chemotherapy. Furthermore, a high infiltration of CD45+ cells was associated with improved 
overall and progression-free survival. A dependency of the prognostic impact of CD8+ and 
CD45+ cells on to the debulking status was found. Similarly, a varying prognostic value of 
residual tumor according to the infiltration of CD8+ and CD45+ cells was revealed. 
In addition, in a small EOC patient cohort of 19 women a moderate correlation between 
the risk to die – according to the prognostic blood cell gene expression panel – and alternatively 
activated macrophages in the tumor tissue was revealed. This association indicates an 
interaction between blood circulating immune cells and tumor associated macrophages.  
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7 Zusammenfassung 
Ovarialkarzinom zählt zu den Krebserkrankungen mit der höchsten Mortalität bei Frauen. 
Aufgrund mangelnder Symptome und des Fehlens in der Routine einsetzbarer Screeningmarker 
wird bei den meisten Patientinnen Ovarialkarzinom in einem bereits fortgeschrittenen Stadium 
diagnostiziert, mit einer Fünf-Jahres-Überlebensrate von unter 40%. Um das Gesamtüberleben 
zu verbessern, werden daher neue diagnostische und prognostische Marker dringend benötigt. 
In unserem Labor wurden eine Genexpressionssignatur für die Frühdiagnose von epithelialem 
Ovarialkarzinom (EOK) und eine weitere für die Prognostik von EOK-Patientinnen in einer 
mittels Dichtegradienten isolierten Blutleukozytenfraktion entwickelt. Neben 
Blutzellgenexpressionen zielen weitere vielversprechende prognostische Marker in  
EOK-Patientinnen auf Tumorproliferation und tumorinfiltrierende Leukozyten ab. 
Im Laufe dieser Diplomarbeit wurden die Genexpressionen der zwei Blutzellsignaturen 
mit Reverse Transkriptase quantitative PCR in verschiedenen Blutzellfraktionen von 23 
Patientinnen mit EOK, anderen Krebserkrankungen und gutartigen gynäkologischen 
Erkrankungen analysiert. Ziel war es, Blutzellfraktionen zu finden, die für die Bestimmung der 
Gensignaturen geeignet sind und die Dichtegradienten-Methode vereinfachen. Die Analyse des 
diagnostischen Panels zeigte die höchsten krankheitsspezifischen Genexpressionsunterschiede 
in den CD3+, CD19+, CD44+ und CD25+ angereicherten Zellfraktionen. Die meisten Gene des 
prognostischen Panels hatten in den CD14+ und CD25+ angereicherten Zellfraktionen die 
höchsten Expressionswerte, was darauf hindeutet, dass diese Gene vor allem von Zellen der 
Monozytenlinie und aktivierten Leukozyten exprimiert werden. 
Zudem wurden Tumorproliferation, gemessen durch Ki67 Expression, und 
tumorinfiltrierende CD8+, CD68+ und CD45+ Zellen in einer immunhistochemischen Analyse 
mit mehr als 200 EOK-Patientinnen auf ihren prognostischen Wert hin untersucht. Es wurde 
ein stark verringertes Gesamtüberleben für eine kleine Patientinnenpopulation mit sehr wenigen 
Ki67+ Tumorzellen festgestellt, vermutlich aufgrund eines schlechteren Ansprechens auf die 
Chemotherapie. Zudem konnte eine hohe Infiltration von CD45+ Zellen mit längerem 
Überleben assoziiert werden. Es wurde ein vom Resttumorstatus abhängiger positiver Effekt 
der CD8+ und CD45+ Zellen auf das Gesamtüberleben aufgezeigt sowie eine Abhängigkeit des 
prognostischen Werts des Resttumorstatus von der CD8+ und CD45+ Zellinfiltration. 
Außerdem wurde in einer kleinen EOK-Patientinnenkohorte von 19 Frauen eine 
moderate Korrelation zwischen dem mit der prognostischen Blutzellsignatur ermittelten 
Sterberisiko und alternativ aktivierten Makrophagen im Tumorgewebe gefunden. Dies weist 
auf eine Interaktion zwischen Blut zirkulierenden Immunzellen und tumorassoziierten 
Makrophagen hin. 
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